Publications

1. Sacubitril-Based Urea and Thiourea Derivatives as Novel Inhibitors for Anti-Tubercular against Dormant Tuberculosis. S. Konduri, V. Pogaku, J. Prashanth, V.S. Krishna, D. Sriram, S. Basavoju, J.N. Behera, K.P. Rao. ChemistrySelect, 6, 3869-3874, 2021.
2. Inhibition of double stranded RNA dependent protein kinase (PKR) abrogates isoproterenol induced myocardial ischemia in vitro in cultured cardiomyocytes and in vivo in wistar rats. S Mangali, A. Bhat, D. Dasari, D. Sriram, A. Dhar. Eur. J. Pharmacol. 906, 174223, 2021.
   
   
3. S-alkylated thiosemicarbazone derivatives: Synthesis, crystal structure determination, antimicrobial activity evaluation and molecular docking studies. M.G. Gunduz, B. Kaya, C. Ozkul, O. Sahin, E.M. Rekha, D. Sriram, B. Ulkuseven. J. Mol. Str. 1242, 130674, 2021.
4. Anthrylphosphonate and π-conjugated acid cocrystal as a Mycobacterium tuberculosis inhibitor: Role of P=O...H interactions. B. Prusti, V.S. Krishna, D. Sriram, M. Chakravarty. J. Mol. Str. 1241, 130642, 2021.
5. A stereo, regioselective synthesis and discovery of antimycobaterium tuberculosis activity of novel β-lactam grafted spirooxindolopyrrolidine hybrid heterocycles. N. Arumugam, AI. Almansour, R.S. Kumar, V.S. Krishna, D. Sriram, R. Padmanaban. Arabian J. Chem. 14, 102938, 2021.
6. Synthesis and Biological Evaluation of Novel Benzhydrylpiperazine-Coupled Nitrobenzenesulfonamide Hybrids. V.S. Murthy, Y. Tamboli, V.S. Krishna, D. Sriram, F.X. Zhang, G.W. Zamponi, V. Vijayakumar. ACS Omega, 6, 9731-9740, 2021.
7. Stereoselective synthesis and discovery of novel spirooxindolopyrrolidine engrafted indandione heterocyclic hybrids as antimycobacterial agents. N. Arumugam, A.I. Almansour, R.S. Kumar, V.S. Krishna, D. Sriram, N. Dege. Bioorg. Chem. 110, 104798, 2021.
8. Facile microwave-assisted synthesis and antitubercular evaluation of novel aziridine derivatives. P. Sarojini, M. Jeyachandran, D. Sriram, P. Ranganathan, S. Gandhimathi. J. Mol. Str. 1233, 130038, 2021.
9. Design and Synthesis of "chloropicolinate Amides and Urea Derivatives" as Novel Inhibitors for Mycobacterium tuberculosis. S. Konduri, D. Bhargavi, J. Prashanth, V.S. Krishna, D. Sriram, K.P. Rao. ACS Omega. 6, 1657-1667, 2021.
10. Design, synthesis, and biological evaluation of benzo[d]imidazole-2-carboxamides as new anti-TB agents. T.M. Dhameliya, K.I. Patel, R. Tiwari, D. Sriram, A.K. Chakraborti. Bioorg. Chem., 104538, 2021.
11. Synthesis and antimicrobial evaluation of new nitric oxide-donating fluoroquinolone/oxime hybrids. H.A. Aziz, G.A.I. Moustafa, G.E.A. Abuo-Rahma, S.M Rabea, G. Hauk, V.S Krishna, D. Sriram, J.M. Berger, S.H Abbas. Arch Der Pharm. 354, 2000180, 2021.
12. 2,4-Diaminotriazines as anti-infective agents. S.S. De, S.K Vogalu, N. Ansari, R. Patil, D. Sriram, M.S Degani. J. Ind. Chem. Soc. 97, 1211-1215, 2020.
13. Synthesis of isoniazid-1,2,3-triazole conjugates: Antitubercular, antimicrobial evaluation and molecular docking study. P.S. Patil, S.L. Kasare, N.B. Havel, V.M. Khedkar, E.M. Rekha, D. Sriram, K.P.Havel. J. Het. Chem.57, 3544-3557, 2020.
14. Design and synthesis of purine connected piperazine derivatives as novel inhibitors of Mycobacterium tuberculosis. S. Konduri, J. Prashanth, V.S. Krishna, D. Sriram, J.N. Behera, D. Siegel, K.P. Rao. Bioorg. Chem. Lett. 30, 127512, 2020.
15. Design and synthesis of new indanol-1,2,3-triazole derivatives as potent antitubercular and antimicrobial agents. P.S. Phatak, R.D. Bakale, R.S. Kulkarni, S.T. Dhumal, P.P. Dixit, V.S. Krishna, D. Sriram, V.M. Khedkar, K.P Haval. Bioorg. Chem. Lett. 30, 127579, 2020.
16. Synthesis of novel 4,5-dihydropyrrolo[1,2-a]quinoxalines, pyrrolo[1,2-a]quinoxalin]-2-ones and their antituberculosis and anticancer activity. V.B. Makane, E.V. Krishna, U.B Karale, D.A Babar, S. Kalari, E.M Rekha, M. Shukla, G. Kaul, D. Sriram, S. Chopra, S. Misra, H.B Rode. Arch Der Pharm. 353, 2070019, 2020.
17. Ameliorative effect of Papain on Behavioral and Bio-Chemical Alterations in In-Silico and In-Vivo models of Neuropathic Pain in Rats. S. Pokkula, S.R. Thaakur, V.S. Krishna, D. Sriram Res. J. Pharm. .Technol., .13, 3807-3812, 2020.
18. Regio- and diastereoselective synthesis of spiropyrroloquinoxaline grafted indole heterocyclic hybrids and evaluation of their anti-Mycobacterium tuberculosis activity. N. Arumugam, A.I. Almansour, R.S. Kumar, A.J.M.A. Al-Aizari, S.I. Alaqeel, S. Kansiz, V.Siva Krishna, D. Sriram, N. Dege. RSC Advances. 10, 23522-23531, 2020.
19. Design, synthesis and biological evaluation of novel Pseudomonas aeruginosa DNA gyrase B inhibitors. S. Jogula, V.S. Krishna, N. Meda, V. Balraju, D. Sriram. Bioorg. Chem. 100 103905, 2020.
20. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors. S.D. Dogan, M.G. Gündüz, H. Dogan, V.S. Krishna, C. Lherbet, D. Sriram. Eur. J. Med. Chem. 199, 112402, 2020.
21. Pyrazole–coumarin and pyrazole–quinoline chalcones as potential antitubercular agents. G. Kumar, V.S. Krishna, D. Sriram, S.M. Jachak. Arch. Der Pharm. 358, 2000077, 2020.
22. 1,3-Disubstituted urea derivatives: Synthesis, antimicrobial activity evaluation and in silico studies. M.G. Gündüz,S.B. Ugur, F. Güney, C. Özkul, V.S. Krishna, S. Kaya, D. Sriram, S.D. Dogan. Bioorg. Chem, 102, 104104, 2020.
23. Novel isoniazid embedded triazole derivatives: Synthesis, antitubercular and antimicrobial activity evaluation. P.S. Patil, S.L. Kasare, N.B. Haval, V.M. Khedkar, P.P. Dixit, E.M. Rekha, D. Sriram, K.P. Haval. Bioorg. Med. Chem. Lett. 30, 127434, 2020.
24. Antitubercular activity of novel class of spiropyrrolidine tethered indenoquinoxaline heterocyclic hybrids. N. Arumugam, A.I. Almansour, R.S. Kumar, S.. Alqeel, V.S. Krishna, D. Sriram. Bioorg. Chem. 99, 103799, 2020.
25. Upregulation of PKR pathway mediates glucolipotoxicity induced diabetic cardiomyopathy in vivo in wistar rats and in vitro in cultured cardiomyocytes. S. Mangali, A. Bhat, K. Jadhav, J.Kalra, D. Sriram, V.V.K. Venuganti, A. Dhar. Biochem. Pharmacol. 177, 113948, 2020.
26. Benzimidazoquinazolines as new potent anti-TB chemotypes: Design, synthesis, and biological evaluation. P.S. Jadhavar, K.I. Patel, T.M. Dhameliya, N. Saha, M.D. Vaja, V.S. Krishna, D. Sriram, A.K. Chakraborti. Biorg. Chem. 99, 103774, 2020.
27. Design and development of ((4-methoxyphenyl)carbamoyl) (5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)amide analogues as Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors. V.S. Krishna, S. Zheng, E.M. Rekha, R. Nallangi, D.V.S. Prasad, S.E. George, L.W. Guddat, D. Sriram. Eur. J. Med. Chem. 193, 112178, 2020.
28. Synthesis and efficacy of pyrvinium-inspired analogs against tuberculosis and malaria pathogens. V.R. Gaikwad, U.B. Karale, G. Govindarajalu, N. Adhikari, E.V. Krishna, V.S. Krishna, S.Mishra, D.Sriram, P.U. Sijwali, H.B. Rode. Bioorg. Med. Chem. Lett. 30, 127037, 2020.
29. SGLT1 Inhibition Boon or Bane for Diabetes Associated Cardiomyopathy. J. Kalra, S.B. Mangali, D. Dasari, A. Bhat, S. Goel, I. Dhar, D. Sriram, A. Dhar. Fund. Clin. Pharmacol. 173-188, 2020.
30. Anticancer potential of N-sulfonyl noscapinoids: Synthesis and evaluation. P.K.R. Nagireddy, V.K. Kommalapati, V.S. Krishna, D. Sriram, A.D. Tangutur, S. Kantevari. Chem. Select, 5, 2972-2980, 2020.
31. Synthesis and bioevaluation of α,α’-bis(1H-1,2,3-triazol-5-ylmethylene)ketones. T.R. Deshmukh, V.S. Krishna, D. Sriram, J.N. Sangshetti, B.B. Shingate. Chem. Pap. 74, 809-820, 2020.
32. Synthesis of novel 5-chloro-2-(thiophen-2-yl)-7,8-dihydroquinoline-6-carboxamides as potent inhibitors of Mycobacterium tuberculosis. S.K. Marvadi, D. Nagineni, S. Safoora, V.S. Krishna, D. Sriram, S. Kantevari. Monatshefte fur Chemie, 151, 405-415, 2020.
33. Synthesis, in vitro and in vivo (Zebra fish) antitubercular activity of 7,8-dihydroquinolin-5(6H)-ylidenehydrazinecarbothioamides. S.K. Marvadi, V.S. Krishna, G. Surineni, R. S. Reshma, D. Sriram, S. Kantevari. Bioorg. Chem. 96, 103626, 2020.
34. Novel pyrazine based anti-tubercular agents: Design, synthesis, biological evaluation and in silico studies. N.W. Hassan, M.N. Saudi, Y.S. Abdel-Ghany, A. Ismail, P.A. Elzahhar, D. Sriram, R. Nassra, M.M. Abdel-Aziz, S.A. El-Hawash. Bioorg. Chem. 96, 103610, 2020.
35. Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity. M.M. Sirim, V.S. Krishna, D. Sriram, O.U. Tan. Eur. J. Med. Chem. 18, 112010, 2020.
36. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors. H. Dogan, S.D. Dogan, M.G. Gündüz, V.S. Krishna, C. Lherbet, D. Sriram, , O. Sahin, ,E. Saripinar. Eur. J. Med. Chem. 18, 112035, 2020.
37. Synthesis, bioevaluation and molecular docking study of new piperazine and amide linked dimeric 1,2,3-triazoles. T.R. Deshmukh, S.P. Khare, V.S. Krishna, D. Sriram, J.N. Sangshetti, V.M. Khedkar, .B. Shingate. Synth.Commun. 50, 271-288, 2020.
38. 5-Methyl-4-thiazolidinones: Synthesis and evaluation as antitubercular agents. A.S. Ekinci, J. Moncol,V.S. Krishna,D. Sriram, K. Özadali-Sari. J. Res. Pharm. 24, 30-37, 2020.
39. Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents. P.K. Bangalore, V.S. Krishna, R. Bollikonda, D.K. Veeragoni, P.C. Choudante, S. Misra, D. Sriram, S. Balasubramanian, S. Kantevari. J. Nat. Prod. 83, 26-35, 2020.
40. Synthesis of Disulfide‐Bridged N‐Phenyl‐N′‐(alkyl/aryl/heteroaryl)urea Derivatives and Evaluation of Their Antimicrobial Activities. S. D.Dogan, S. Buran, M.G. Gündüz, V.S. Krishna, D. Sriram. Chem. Biodiv. 16, e1900461, 2019.
41. Some new hydrazone derivatives bearing the 1,2,4-triazole moiety as potential antimycobacterial agents. K.O¨. Sari, O.U¨. Tan, D. Sriram, A. Balkan. Turk. J. Pharm. Sci. 16, 432-436, 2019.
42. Synthesis and in vitro Antibacterial, Antitubercular Studies of Novel Fluoroquinolones analogs containing 4-substituted sec. amine. R.K. Akula, S.R. Pamulaparthy, P.K. Koochana, D. Sriram. Curr. Bioactive Comp. 15, 656-664, 2019.
43. Synthesis, bioevaluation and molecular docking study of new piperazine and amide linked dimeric 1,2,3-triazoles. T.R. Deshmukh, S.P. Khare, V.S. Krishna, D. Sriram, J.N. Sangshetti, V.M. Khedkar, B.B. Shingate. Synthetic Communic., 50, 271-288, 2019.
44. Imidazo[2,1-b]thiazole-Coupled Natural Noscapine Derivatives as Anticancer Agents. P.K.R. Nagireddy, V.K. Kommalapati, V.S. Krishna, D. Sriram, A.D. Tangutur, S. Kantevari, ACS Omega, 4, 19382-19398, 2019.
45. The design and green synthesis of novel benzotriazoloquinolinyl spirooxindolopyrrolizidines: antimycobacterial and antiproliferative studies. V. Pogaku, V.S. Krishna, C. Balachandran, K. Rangan, D. Sriram, S. Aoki, S. Basavoju. New J. Chem. 43, 17511-17520, 2019.
46. Molecular Dynamics Studies on COX-2 Protein-tyrosine Analogue Complex and Ligand-based Computational Analysis of Halo-substituted Tyrosine Analogues. A. Puratchikody, A. Umamaheswari, N. Irfan, D. Sriram. Letters in Drug Design & Discovery, 1211-1232, 2019.
47. New N-phenylacetamide-incorporated 1,2,3-triazoles: [Et3NH][OAc]-mediated efficient synthesis and biological evaluation. S.V. Akolkar, A.A. Nagargoje, V.S. Krishna, D. Sriram, J.N. Sangshetti, M. Damale, B.B. Shingate. RSC Adv., 9, 22080-2209, 2019.
48. 5-Chloro-2-thiophenyl-1,2,3-triazolylmethyldihydroquinolines as dual inhibitors of Mycobacterium tuberculosis and influenza virus: Synthesis and evaluation. S.K. Marvadi, V.S. Krishna, E.O.Sinegubova, A.S. Volobueva, Y.L. Esaulkova, A.A. Muryleva, D.G. Tentler, D. Sriram, V.V. Zarubaev, S. Kantevari. Bioorg. Med. Chem. Lett. 29, 2664–2669, 2019.
49. Design and Synthesis of New Aryloxy-linked Dimeric 1,2,3-Triazoles via Click Chemistry Approach: Biological Evaluation and Molecular Docking Study.T.R. Deshmukh, S.P. Khare, V.S. Krishna, D. Sriram, J.N. Sangshetti, O. Bhusnure, V.M. Khedkar, B.B. Shingate. J. Het. Chem. 56, 2144-2162, 2019.
    
    
50. Targeting HIV‐TB coinfection by developing novel piperidin‐4‐substituted imines: Design, synthesis, in vitro and in silico studies. A. Kumar, R.Revathi, D. Sriram, F. Curreli, A.K. Debnath, K.S. Pai, S.G. Kini. Archiv der Pharmazie, 352, 1800358, 2019.
51. Design, synthesis and molecular modeling studies on novel moxifloxacin derivatives as potential antibacterial and antituberculosis agents. A.Türe, N. Kulabas, S.IpekDingis, K. Birgü, A. Bozdeveci, I. Küçükgüzel S.A.Karaoglu, V.S. Krishna, D. Sriram, , I. Küçükgüzel . Bioorg. Chem. 88, 102965, 2019.
52. New fluoroquinolones/nitric oxide donor hybrids: design, synthesis and antitubercular activity. H.A. Aziz, G.A.I. Moustafa, S.H. Abbas, G.Hauk, V.S. Krishna, D. Sriram, J.M. Berger, G. El-Din A. Abuo-Rahma.Med. Chem. Res. 28, 1272-1283, 2019.
53. Ultrasonication-ionic liquid synergy for the synthesis of new potent anti- tuberculosis 1,2,4-triazol-1-yl-pyrazole based spirooxindolopyrrolizidines. V.Pogaku, V.S. Krishna, D. Sriram, K. Rangan, S. Basavoju.Bioorg. Med. Chem. Lett. 29,1682–1687, 2019.
54. Synthesis, antitubercular evaluation and molecular docking studies of phthalimide bearing 1,2,3-triazoles. P.S. Phatak, R.D. Bakale, S.T. Dhumal, L.K. Dahiwade, P.B. Choudhari, V.S. Krishna, D. Sriram, K.P. Haval. Syn. Commun., 49, 2017-2028, 2019.
55. Synthesis and biological evaluation of 2,4,5-trisubstituted thiazoles as antituberculosis agents effective against drug-resistant tuberculosis. U.B. Karale, V.S. Krishna, E.V. Krishna, A.S. Choudhari, M. Shukla, V.R. Gaikwad, B. Mahizhaveni, S. Chopra, S. Misra, D. Sarkar, D. Sriram, V.N.A. Dusthackeer, H.B. Rode. Eur. J. Med. Chem. 178, 315-328, 2019.
56. Discovery and evaluation of novel Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors as therapeutic drug leads. V.S. Krishna, S. Zheng, E.M. Rekha, L.W. Guddat, D. Sriram. J. Computer-Aided Mol. Des. 33, 357-366, 2019.
57. Novel 1,3,4-oxadiazoles as antitubercular agents with limited activity against drug-resistant tuberculosis. V.B. Makane, V.S. Krishna, E.V. Krishna, M. Shukla, B. Mahizhaveni, S. Mishra, S. Chopra, D. Sriram, V.N.A. Dusthackeer, H.B. Rode. Future Med. Chem. 11, 499-510, 2019.
58. Synthesis and evaluation of novel substituted 1,2,3- triazolyldihydroquinolines as promising antitubercular agents. T.S.K. Marvadi, V.S. Krishna, D. Sriram, S. Kantevari.Bioorg. Med. Chem. Lett. 29, 529–533, 2019.
59. Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents. K.Sharma, O. Tanwar, G.S. Deora., S. Ali, M.M. Alam, M.S. Zaman, V.S. Krishna, D. Sriram, M. Akhter. Bioorg. Med. Chem. 27, 1421–1429, 2019.
60. Inhibition of protein kinase R protects against palmitic acid-induced inflammation, oxidative stress, and apoptosis through the JNK/NF-kB/NLRP3 pathway in cultured H9C2 cardiomyocytes. S. Mangali, A. Bhat, M.P. Udumula, I. Dhar, D. Sriram, A. Dhar. J Cell Biochem. 120, 3651-3663, 2019.
61. Synthesis and evaluation of a-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis. V.B. Makane, V.S. Krishna, E.V. Krishna, M. Shukla, B. Mahizhaveni, S. Misra, S. Chopra, D. Sriram,
    V.N.A. Dusthackeer, H.B. Rode. Eur. J. Med. Chem. 164, 665-677, 2019.
62. Synthesis of novel morpholine, thiomorpholine and N-substituted piperazine coupled 2-(thiophene-2-yl)dihydroquinolines as potent inhibitors of Mycobacterium tuberculosis. S. K. Marvadi, V.S. Krishna, D. Sriram, S. Kantevari. Eur. J. Med. Chem. 164, 171-178, 2019.
63. Synthesis and biological evaluation of 1H-pyrrolo[2,3-d]pyrimidine-1,2,3- triazole derivatives as novel anti-tubercular agents. K.S. Raju, S.A. Reddy, G. Sabitha, V.S. Krishna, D. Sriram, K. B. Reddy, S.R. Sagurthi. Bioorg. Med. Chem. Lett. 29, 284–290, 2019.
64. α-Sulfonamidophosphonates as New Anti-Mycobacterial Chemotypes: Design, Development of Synthetic Methodology, and Biological Evaluation. S. Bhagat, M. Supriya, S. Pathak, D. Sriram, A.K. Chakraborti. Bioorg. Chem. 82, 246-252, 2019.
65. Design, Synthesis and Molecular Docking Studies of Novel Triazole-Chromene Conjugates as Antitubercular, Antioxidant and Antifungal Agents. S.P. Khare, T.R.Deshmukh, J.N.Sangshetti, V.S.Krishna, D. Sriram, V.M. Khedkar,B.B. Shingate,Chemistry Select3, 13113-13122, 2018.
66. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations. S. Saxena, M. Abdullah, D. Sriram, L. Guruprasad. J. Biomol. Str. Dyn. 36, 3184-3198, 2018.
67. Rational design of coumarin derivatives as antituberculosis agents. H. M. Mali, S. S Sabale, M. S. Degani, R. Borkute, A. S. Choudhari, D. Sarkar, V. S. Krishna, D. Sriram. Future Med. Chem. 10, 2431-2444, 2018.
68. A quinoline compound inhibits the replication of dengue virus serotypes 1-4 in Vero cells. H. Beesetti, P. Tyagi, B. Medapi, V.S. Krishna, D. Sriram, N. Khanna, S. Swaminathan. Antivir Ther. 23, 385-2394, 2018.
69. Pharmacological evaluation of novel PKR inhibitor indirubin-3-hydrazone in-vitro in cardiac myocytes and in-vivo in wistar rats. M.P. Udumula, A. Bhat, S. Mangali, J. Kalra, I. Dhar, D. Sriram, A. Dhar. Life Sci. 209, 85-96, 2018.
70. Clickable conjugates of bile acids and nucleosides: Synthesis, characterization, in vitro anticancer and antituberculosis studies. D.S. Agarwal, V. Siva Krishna, D. Sriram, P. Yogeeswari, R. Sakhuja. Steroids 139, 35-44, 2018.
71. Amsacrine Derivatives Selectively Inhibit Mycobacterial Topoisomerase I (TopA), Impair M. smegmatis Growth and Disturb Chromosome Replication. M. J. Szafran, M. Kolodziej, P. Skut, B. Medapi, A. Domagala, D. Trojanowski, J. Zakrzewska-Czerwin ´ska, D. Sriram, D. Jakimowicz.Front. Microbiol. 9:1592, 2018.
72. Synthesis and biological evaluation of dihydroquinoline carboxamide derivatives as anti-tubercular agents. G. Kumar, A. Sathe, V.S. Krishna, D. Sriram, S. M. Jachak.Eur. J. Med. Chem. 157, 1-13, 2018.
73. Synthesis of carbohydrazides and carboxamides as anti-tubercular agents. G. Kumar, V. S. Krishna, D. Sriram, S. M. Jachak.Eur. J. Med. Chem. 156, 871-884, 2018.
74. Structure-based design of some isonicotinic acid hydrazide analogues as potential antitubercular agents Amal Atta, Salwa Fahmy, Ola Rizk, Dharmarajan Sriram, Mona A. Mahran, Ibrahim M. Labouta. Bioorg. Chem. 80, 721-732, 2018.
75. Design, Synthesis and in vitro anti-tubercular activity of 1,2,3-triazolyl-dihydroquinoline derivatives. S. Banu, R. Bollu, L. Nagarapu, J.B Nanubolu,Y. Perumal, D. Sriram, S.K. Gunda, D. Vardhan. Chem Biol Drug Des. 92, 1315-1323, 2018.
76. Benzo[d]thiazole-2-carbanilides as new anti-TB chemotypes: Design, synthesis, biological evaluation, and structure-activity relationship. T.M. Dhameliya, R. Tiwari, A. Banerjee, S. Pancholia, D. Sriram, D. Panda, A.K. Chakraborti. Eur J Med Chem. 155, 364-380, 2018.
77. 1,2,3-Triazole-fused spirochromenes as potential anti-tubercular agents: synthesis and biological evaluation. D. Ashok, P. Chiranjeevi,A. V. Kumar,M. Sarasija,V. S. Krishna,D. Sriram,
    S. Balasubramanian. RSC Adv., 8, 16997–17007, 2018.
78. Dibenzofuran, dibenzothiophene and N-methyl carbazole tethered 2-aminothiazoles and their cinnamamides as potent inhibitors of Mycobacterium tuberculosis. G. Surineni, S.K. Marvadi, P. Yogeeswari, D.Sriram, S. Kantevari. Bioorg Med Chem Lett. 28, 1610-1614, 2018.
79. Identification of potent chromone embedded [1,2,3]-triazoles as novel anti-tubercular agents. V. Nalla, A. Shaikh, S. Bapat, R. Vyas, M. Karthikeyan, P. Yogeeswari, D. Sriram, M. Muthukrishnan. R. Soc. open sci.5, 171750, 2018.
80. In silico design of small peptides antagonist against leptin receptor for the treatment of obesity and its associated immune-mediated diseases. M. Munikumar, V.S. Krishna, V.S. Reddy, B. Rajeswari, D. Sriram, M.V. Rao. J. Mol. Graph. Modell. 82, 20-36, 2018.
81. Synthesis and Evaluation of 4',5'-Dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] Analogues Against Both Active and Dormant Mycobacterium tuberculosis. K. K, Alluri, R. S. Reshma, R. Suraparaju, S. Gottapu, D. Sriram,Bioorg. Med. Chem. 26, 1462–1469, 2018.
82. Identification and Development of Novel Indazole Derivatives as Potent Bacterial Peptidoglycan Synthesis Inhibitors. P. Malapati, K.S. Vagolu, D. Sriram.Int J Mycobacteriol, 7, 76‐83, 2018.
83. Identification and Development of Oxoquinazoline Derivatives as Novel Mycobacterial Inhibitors Targeting Cell Wall Synthesis Enzyme. P. Malapati, K.S. Vagolu, D. Sriram. Biomed. Biotechnol. Res. 2, 31-38, 2018.
    
    
84. Identification and development of benzoxazole derivatives as novel bacterial glutamate racemaseinhibitors. P. Malapati, V.S. Krishna, R. Nallangi, R.R. Srilakshmi, D. Sriram. Eur J Med Chem. 145, 23-34, 2018.
85. Lead identification and optimization of bacterial glutamate racemase inhibitors. P. Malapati, V.S. Krishna, R. Nallangi, N. Meda, R.R. Srilakshmi, D. Sriram. Bioorg Med Chem. 26, 177-190, 2018.
86. Design, synthesis, and in vitro antituberculosis activity of benzo[6,7]cyclohepta[1,2-b]pyridine-1,3,4-oxadiazole derivatives. Y. Sajja, S. Vanguru, H.R. Vulupala, L. Nagarapu, Y. Perumal, D. Sriram, J.B. Nanubolu. Chem Biol Drug Des. 90, 496-500, 2017.
87. Polymer–gold nanoparticle composite films for topical application: Evaluation of physical properties and antibacterial activity P.K. Mandapalli, S. Labala, S. Chawla, R. Janupally, D. Sriram, V.V.K. Venuganti. Polymer Composites, 38, 2829-2840, 2017.
88. Synthesis, Crystal Structure and Antimycobacterial Activities of 4-Indolyl-1,4-Dihydropyridine Derivatives Possessing Various Ester Groups., E. Baydar, M.G. Gunduz, V. S. Krishna, R. Simsek, D. Sriram, S. O. Yildirim, R.J. Butcher, C. Safak. Research on Chemical Intermediates. 43, 7471-7489, 2017.
89. Inhibition of Tyrosinase by 4H-Chromene Analogues: Synthesis, Kinetic Studies and Computational Analysis. E.M. Brasil, L.M. Canavieira, E.T. Cardoso, E.O. Silva, J. Lameira, J.L. Nascimento, V.L. Eifler-Lima, B. de Matos Macchi, D. Sriram, P.V. Bernhardt, J.R. Silva, C.M. Williams, C.N. Alves. Chem Biol Drug Des. 90, 804-810, 2017.
90. Bis-spirochromanones as potent inhibitors of Mycobacterium tuberculosis: synthesis and biological evaluation. A.Dongamanti , V.K. Aamate, M.G. Devulapally, S. Gundu, S. Balabadra, V. Manga, P. Yogeeswari, D. Sriram, S. Balasubramanian. Mol Divers. 21, 999-1010, 2017.
91. Design and synthesis of novel triazole linked pyrrole derivatives as potent Mycobacterium tuberculosis inhibitors. M.L. Devi, P.L. Reddy, T.V. Reddy,B.V.S. Reddy, Medicinal Chemistry ResearchDevi, P.L. Reddy, T.V. Reddy,B.V.S. Reddy, Medicinal Chemistry Research P. Yogeeswari, D. Sriram, Devi, P.L. Reddy, T.V. Reddy,B.V.S. Reddy, Medicinal Chemistry ResearchDevi, P.L. Reddy, T.V. Reddy,B.V.S. Reddy, Medicinal Chemistry ResearchR. Narender. Devi, P.L. Reddy, T.V. Reddy,B.V.S. Reddy, Medicinal Chemistry Research, 26, 2985-2999, 2017.
92. Correlation of pharmacokinetics and brain penetration data of adult zebrafish with higher mammals including humans. P. Kulkarni, R. Medishetti, N. Nune, S. Yellanki, V. Sripuram, P. Rao, D. Sriram, U. Saxena, S. Oruganti, P. Yogeeswari. J Pharmacol Toxicol Methods. 88, 147-152, 2017.
93. Design, synthesis and in vitro anti-tuberculosis activity of benzo[6,7]cyclohepta[1,2-b]pyridine-1,2,3-triazole derivatives. Y. Sajja, S. Vanguru, H.R. Vulupala, R. Bantu, P. Yogeswari, D. Sriram, L. Nagarapu. Bioorg Med Chem Lett. 27, 5119-5121, 2017.
94. Profiling of in vitro activities of urea-based inhibitors against cysteine synthases from Mycobacterium tuberculosis. K. Brunner, E.M. Steiner, R.S. Reshma, D. Sriram, R. Schnell, G. Schneider. Bioorg Med Chem Lett.27, 4582-4587, 2017.
95. Reshma, V.U. Jeankumar, N. Kapoor, S. Saxena, K.A. Bobesh, A.R. Vachaspathy, P.E. Kolattukudy, D.Mycobacterium tuberculosis lysine-?-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors. R.S. Sriram. Bioorg Med Chem. 25, 2761-2771, 2017.
96. Layer-by-Layer Thin Films for Co-Delivery of TGF-β siRNA and Epidermal Growth Factor to Improve Excisional Wound Healing. P. K. Mandapalli, S. Labala, A. Jose, S. Bhatnagar, R. Janupally, D. Sriram, V.V. K. Venuganti, AAPS PharmSciTech 18, 809-820, 2017.
97. Synthesis and anti-mycobacterial activity of 4-(4-phenyl-1H-1,2,3-triazol-1-yl)salicylhydrazones: revitalizing an old drug. H.H. Abdu-Allah, B.G. Youssif, M.H. Abdelrahman, M.K. Abdel-Hamid, R.S. Reshma, P. Yogeeswari, T. Aboul-Fadl, D. Sriram. Arch. Pharmacal Res. 40, 168-179, 2017.
98. Synthesis, molecular docking, antimycobacterial and antimicrobial evaluation of new pyrrolo[3,2-c]pyridine Mannich bases. G. Jose, T.H.S. Kumara, H.B. Sowmya, D. SriramT.N.G. Row, A.A. Hosamani, S.S. More, B. Janardhan, B.G. Harish, S. Telkar, Y.S. Ravikumar. Eur J Med Chem. 131, 275-288, 2017.
99. High glucose impairs insulin signaling via activation of PKR pathway in L6 muscle cells. M.P. Udumula, M.S. Babu, A. Bhat, I. Dhar, D. Sriram, A. Dhar. Biochem Biophys Res Commun. 486, 645-651, 2017.
100. Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors. P.S. Salve, S.G. Alegaon, D. Sriram. Bioorg Med Chem Lett. 27, 1859-1866, 2017.
101. A robust synthesis of functionalized 2H-indazoles via solid state melt reaction (SSMR) and their anti-tubercular activity. S. Vidyacharan, C. Adhikari, V.S. Krishna, R.S. Reshma, D. Sriram, D.S. Sharada. Bioorg Med Chem Lett. 27,1593-1597, 2017.
102. Design, synthesis, molecular-docking and antimycobacterial evaluation of some novel 1,2,3-triazolyl xanthenones. G. L. Goud, S. Ramesh, D. Ashok, V. P. Reddy, P. Yogeeswari, D. Sriram, B. Saikrishna, V. Manga. Med. Chem. Commun., 8, 559-570, 2017.
103. A Facile Synthesis and Antituberculosis Properties of Almazole D and Its Enantiomer, D.M. Lade, V.S. Krishna, D. Sriram, H.B. Rode. CHEMISTRYSELECT, 2, 1250-1252, 2017.
104. Novel Zebrafish EAE model: A quick in vivo screen for multiple sclerosis. P. Kulkarni, S. Yellanki, R. Medishetti, D. Sriram, U. Saxena, P. Yogeeswari. Mult. Scler. Relat. Disord. 11, 32-39, 2017.
105. Novel Thiazolidinone-Azole Hybrids: Design, Synthesis and Antimycobacterial Activity Studies. B. Eroglu, K. Ozadali-Sari, O. Unsal-Tan, D. Sriram, P. Yogeeswari, A. Balkan. Iran J. Pharm. Res. 15, 783-790, 2016.
106. Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads. B. Tanwar, A. Kumar, P. Yogeeswari, D. Sriram, A.K. Chakraborti. Bioorg. Med. Chem. Lett. 26, 5960-5966, 2016.
107. Design and development of new class of Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors. R.S. Reshma, S. Saxena, K.A. Bobesh, V.U. Jeankumar, S. Gunda, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. 24, 4499–4508, 2016.
108. Pharmacological evaluation of novel alagebrium analogs as methylglyoxal scavengers in vitro in cardiac myocytes and in vivo in SD rats. A. Dhar, M.P. Udumula, B. Medapi, A. Bhat, I. Dhar, P. Malapati, M.S. Babu, J. Kalra, D. Sriram, K.M. Desai. Int. J. Cardiol. 223, 581–589, 2016.
109. A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis. Y. Sajja, S. Vonguru, L. Jilla, H.R. Vulupala, R. Bantu, P. Yogeswari, D. Sriram, L. Nagarapu. Bioorg. Med. Chem. Lett. 26, 4292–4295, 2016.
110. Inhibitors of the Cysteine Synthase CysM with Antibacterial Potency against Dormant Mycobacterium tuberculosis. K. Brunner, S. Maric, R.S. Reshma, H. Almqvist, B. Seashore-Ludlow, A.L. Gustavsson, Ö. Poyraz, P. Yogeeswari, T. Lundbäck, M. Vallin, D. Sriram, R. Schnell, G. Schneider. J. Med. Chem., 59, 6848–6859, 2016.
111. Click-based synthesis and antitubercular evaluation of dibenzofuran tethered thiazolyl-1,2,3-triazolyl acetamides. G. Surineni, P. Yogeeswari, D. Sriram, K. Srinivas. Bioorg. Med. Chem. Lett. 26, 3684–3689, 2016.
112. Synthesis and anti-mycobacterial activity of 1H-1,2,3-triazolylisonicotinohydrazides. Ch. Dayakar, P. Suman, K. Rajkumar, P. Yogeeswari, D. Sriram, B.C. Raju. Ind. J. Chem (B), 55, 882-887, 2016.
113. Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors. V.U. Jeankumar, R.S. Reshma, R. Vats, R. Janupally, S. Saxena, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 122, 216-231, 2016.
114. Targeting multiple response regulators of Mycobacterium tuberculosis augments the host immune response to infection. S. K. Banerjee, M. Kumar, R. Alokam, A. K. Sharma, A. Chatterjee, R. Kumar, S. K. Sahu, K. J. R. Singh, P. Yogeeswari, D. Sriram, J. Basu, M. Kundu, Scientific Reports (Nature) 6, Article number: 25851, 2016.
     
     
115. Click-based synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene-1,2,3-triazoles with piperidine, piperazine, morpholine and thiomorpholine appendages. L. Pulipati, P. Yogeeswari, D. Sriram, S. Kantevari. Bioorg. Med. Chem. Lett. 26, 2649-2654, 2016.
116. Synthesis, biological evaluation and structure–activity relationship of 2-styrylquinazolones as anti-tubercular agents, P. S. Jadhavar, T. M. Dhameliya, M. D. Vaja, D. Kumar, P. Yogeeswari, D. Sriram, A. K. Chakraborti. Bioorg. Med. Chem. Lett. 26, 2663-2669, 2016.
117. Synthesis, molecular properties prediction and anticancer, antioxidant evaluation of new edaravone derivatives. N. Polkam, V. R. Ramaswamy, P. Rayam, T. R. Allaka, H. S. Anantaraju, D. Sriram, P. Yogeeswari, D. Gandamalla, N. R. Yellu, S. Balasubramanian, J. S. Anireddy. Bioorg. Med. Chem. Lett. 26, 2562-2568, 2016.
118. Synthesis and antitubercular activity of fused thieno/-furano quinolone compounds. M. Akula, P. Yogeeswari, D.Sriram, M. Jha, A. Bhattacharya, RSC Advances, 6, 46073-46080, 2016.
119. 3-D structural interactions and quantitative structural toxicity studies of tyrosine derivatives intended for safe potent inflammation treatment. A. Puratchikody, D. Sriram, A. Umamaheswari, N. Irfan. Chemistry Central Journal 10, 24, (DOI 10.1186/s13065-016-0169-9) 2016.
120. Cathepsin D inhibitors as potential therapeutics for breast cancer treatment: Molecular docking and bioevaluation against triple-negative and triple-positive breast cancers. H.S. Anantaraju, M.B. Battu, S. Viswanadha, D. Sriram, P. Yogeeswari. Mol. Divers. 20, 521-535, 2016.
121. Benzo[d]thiazol-2-yl(piperazin-1-yl)methanones as new anti-mycobacterial chemotypes: Design, synthesis, biological evaluation and 3D-QSAR studies. S. Pancholia, T.M. Dhameliya, P. Shah, P.S. Jadhavar, P. Yogeeswari, D. Sriram, A.K. Chakraborti. Eur. J. Med. Chem. 116, 187-199, 2016.
122. Design, Synthesis, and Molecular Docking Studies of a Conjugated Thiadiazole–Thiourea Scaffold as Antituberculosis Agents. E. Tatar, S. Karakus, S.G. Küçükgüzel, S.Ö. Okullu, N. Ünübol, T. Kocagöz, E. DeClercq, G. Andrei, R. Snoeck, C. Pannecouque, S. Kalayci, F. Sahin, D. Sriram, P. Yogeeswari, I. Küçükgüzel. Biol. Pharm. Bull. 39, 502–515, 2016.
123. Synthesis of new pyrazole-triazole hybrids by click reaction using a green solvent and evaluation of their antitubercular and antibacterial activity. N. Nayak, J. Ramprasad, U. Dalimba , P. Yogeeswari, D. Sriram, H.S.S. Kumar, S.K. Peethamber, R. Achur. Res. Chem. Intermediates. 42, 3721-3741, 2016.
124. Synthesis and antimycobacterial screening of new N-(4-(5-aryl-3-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazol-1-yl)phenyl)-4-amide derivatives . N. Nayak, J. Ramprasad, U. Dalimba, P. Yogeeswari, D. Sriram. Chinese Chem. Lett., 27, 365–369, 2016.
125. Structure-Guided Discovery of Antitubercular Agents That Target the Gyrase ATPase Domain. V.U. Jeankumar, S. Saxena, R. Vats, R.S. Reshma, R. Janupally, P. Kulkarni, P. Yogeeswari, D. Sriram. ChemMedChem. 11, 539-548, 2016.
126. Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors. G. Samala, P.B. Devi, S. Saxena, N. Meda, P. Yogeeswari,D. Sriram. Bioorg. Med. Chem. 24, 1298-1307, 2016.
127. Synthesis, Characterization and Biological evaluation of Bile acid-aromatic/heteroaromatic amides linked via amino acids as anti-cancer agents. D.S. Agarwal, H.S. Anantaraju, D. Sriram, P. Yogeeswari, S.H. Nanjegowda, P. Mallu, R. Sakhuja. Steroids, 107, 87-97, 2016.
128. Ionic liquid promoted one-pot synthesis of thiazole-imidazo[2,1-b] [1,3,4]thiadiazole hybrids and their antitubercular activity. J. Ramprasad, N. Nayak, U. Dalimba, P. Yogeeswari, D. Sriram. Med. Chem. Commun., 7, 338-344, 2016.
129. Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors. B. Medapi, N. Meda, P. Kulkarni, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem., 24, 877–885, 2016.
130. Energy Based Pharmacophore and 3D QSAR Modeling Combined with Virtual Screening to Identify Novel Small Molecule Inhibitors of SIRT1. V. Pulla, S. Dinavahi, S. Viswanadha, D. Sriram, P. Yogeeswari. J. Chem. Inf. Model., 56, 173–187, 2016.
131. Design and Development of Mycobacterium tuberculosis Lysine ?-Aminotransferase Inhibitors for Latent Tuberculosis Infection. P.B. Devi, S. Saxena, M. Chandran, R. Yadav, R.R. Srilakshmi, P. Yogeeswari, D. Sriram.
     Chem. Biol. Drug Des. 87, 265-274, 2016.
132. Synthesis of novel 5-[(1,2,3-triazol-4-yl)methyl]-1-methyl-3H-pyridazino[4,5-b]indol-4-one derivatives by click reaction and exploration of their anticancer activity. N. Panathur, N. Gokhale, U. Dalimba, P. V. Koushik, P. Yogeeswari, D. Sriram. Med. Chem. Res. 25, 135-148, 2016.
133. Synthesis of new spirooxindole derivatives through 1,3-dipolar cycloaddition of azomethine ylides and their antitubercular activity. F. Rouatbi, M. Askri, F. Nana, G. Kirsch, D. Sriram, P. Yogeeswari. Tetrahed. Lett. 57, 163–167, 2016.
134. Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors. K. A. Bobesh, J. Renuka, R. R. Srilakshmi, S Yellanki, P. Kulkarni, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. 24, 42–52, 2016.
135. Computational Sampling and Simulation Based Assessment of Novel Mycobacterium tuberculosis Glutamine Synthetase Inhibitors: Study involving Structure Based Drug Design and Free Energy Perturbation. P. S. devara, P. Yogeeswari, V. Soni, P.B. Devi, V.K. Nandicoori, D. Sriram. Curr Top Med Chem. 16, 978-995, 2016.
136. Synthesis and biological evaluation of novel N1-decyl and C7- Sec amine substituted fluoroquinolones as antitubercular and anticancer agents. A.R. Kumar, B.P.V. Lingaiah, P.S. Rao, B. Narasaiah, D.Sriram, P. Sowjanya. Ind. J. Chem. 54B, 1495-1501, 2015.
137. A Novel, Potent, Small Molecule AKT Inhibitor Exhibits Efficacy against Lung Cancer Cells In Vitro. S.S. Dinavahi, R. Prasanna, D. Sriram, P. Yogeseswari, S. Viswanadha. Cancer Res. Treat. 47, 913-920, 2015.
138. Spirochromone-chalcone conjugates as antitubercular agents: synthesis, bio evaluation and molecular modeling studies. M. Mujahid, P. Yogeeswari, D. Sriram, U.M.V. Basavanag, E. D´iaz-Cervantes, L. C´ordoba-Bahena, J. Robles, R.G. Gonnade, M. Karthikeyan, Renu Vyas, M. Muthukrishnan. RSC Adv., 5, 106448–106460, 2015.
139. Discovery of novel lysine ?-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis. P.B. Devi, S.S. Kakan, S. Saxena, V.U. Jeankumar, V. Soni, H.S.A. Raju, P. Yogeeswari, D. Sriram. Tuberculosis (Edinb). 95, 786-794, 2015.
140. Depletion of M. tuberculosis GlmU from Infected Murine Lungs Effects the Clearance of the Pathogen. V. Soni, S. Upadhayay, P.S. Devara, G. Samla, A. Singh, P. Yogeeswari, D. Sriram, V.K. Nandicoori. PLoS Pathog. 11(10): e1005235, 2015.
141. The Small Molecule Indirubin-3'-Oxime Inhibits Protein Kinase R: Antiapoptotic and Antioxidant Effect in Rat Cardiac Myocytes. M.P. Udumula, B. Medapi, I. Dhar, A. Bhat, K. Desai, D. Sriram, A. Dhar. Pharmacology. 97, 25-30, 2016.
142. Structural Models for the Design of PKMzeta Inhibitors with Neurobiological Indications P. Purkayastha, R. Alokam, A. Malapati, D. Sriram, P. Yogeeswari. Mol. Inf. 34, 665-678, 2015.
143. Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening. V.K. Pulla, D.S. Sriram, V. Soni, S. Viswanadha, D. Sriram, P. Yogeeswari. Chem Biol Drug Des. 86, 881-894, 2015.
144. Sugar-boronate ester scaffold tethered pyridyl-imine palladium(ii) complexes: synthesis and their in vitro anticancer evaluation. E.R. Reddy, R. Trivedi, A.V. Sarma, B. Sridhar, H.S.A. Raju, D. Sriram, P. Yogeeswari, N. Nagesh. Dalton Trans. 44, 17600-17616, 2015.
145. One-pot synthesis of new triazole-Imidazo[2,1-b][1,3,4]thiadiazole hybrids via click chemistry and evaluation of their antitubercular activity. J. Ramprasad, N. Nayak, U. Dalimba, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. Lett. 25, 4169-4173, 2015.
146. Design of novel dispirooxindolopyrrolidine and dispirooxindolopyrrolothiazole derivatives as potential antitubercular agents. C. Mhiri, S. Boudriga, M. Askri, M. Knorr, D. Sriram, P. Yogeeswari, F. Nana, C. Golz, C. Strohmann C. Bioorg Med Chem Lett. 25, 4308-4313, 2015.
147. Antinociceptive properties of the aqueous and methanol extracts of the stem bark of petersianthus macrocarpus(p. Beauv.) Liben (lecythidaceae) in mice. F.D.T. Bomba, B. A. Wandji, B.N. Piegang, M.D. Awouafack, D. Sriram, P. Yogeeswari, A. Kamanyi, T.B. Nguelefack. J. Ethnopharmacol. 174, 66-73, 2015.
148. Design and Biological Evaluation of Furan/Pyrrole/Thiophene-2-carboxamide Derivatives as Efficient DNAGyraseB Inhibitors of Staphylococcus aureus. R. Janupally, B. Medepi, P. B. Devi, P.S. Devara, V.U. Jeankumar, P. Kulkarni, P. Yogeeswari, D. Sriram. Chem Biol Drug Des. 86, 918-925, 2015.
149. 4-Aminoquinoline Derivatives as Novel Mycobacterium tuberculosis GyrB Inhibitors: Structural Optimization, Synthesis and Biological Evaluation. M. Brahmam, P.S. Devara, J. Renuka, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 103, 1-16, 2015.
150. Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNAgyraseB inhibitors. B. Medapi, J. Renuka, S. Saxena, R. Medishetti, P. Kulkarni, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. 23, 2062-2078, 2015.
151. Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting throughthe inhibitionof the gyrase ATPase domain: lead optimization and structure activity profiling. V.U. Jeankumar, R.S. Reshma, R. Janupally, S. Saxena, B. Medapi, P. Kulkarni, P. Yogeeswari, D. Sriram. Org. Biomol. Chem. 13, 2423-2431, 2015.
152. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novelclass of thiazole inhibitors. V.U. Jeankumar, S. Kotagiri, R. Janupally, P. S. Devara, R. Medishetti, P. Kulkarni, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. 23, 588-601, 2015.
153. Design and development of novel Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors. S. Saxena, G. Samala, P.B. Devi, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 92, 401-414, 2015.
154. Identification of potential Mycobacterium tuberculosis topoisomerase I inhibitors: a study against active,dormant and resistant tuberculosis. J.P.S. Devi, P. S. Devara, R. Janupally, J. Sridhar, V. Soni, H.S.A. Raju, P. Yogeeswari, D. Sriram. Eur. J. Pharm. Sci. 72, 81-92, 2015.
155. Development of 2-amino-5-phenylthiophene-3- carboxamide derivatives as novel inhibitors of Mycobacteriumtuberculosis DNA GyrB domain. S. Saxena, G. Samala, J. Renuka, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. 23, 1402-1412, 2015.
156. Structure based virtual screening as a tool for the identification of novel inhibitors against Mycobacteriumtuberculosis 3-dehydroquinate dehydratase. G.O. Petersen, S. Saxena, J. Renuka, V. Soni, P. Yogeeswari, D.S. Santos, C.V. Bizarro, D. Sriram. J. Mol. Graph. Model. 60, 124-131, 2015.
157. A Review on GABA/Glutamate Pathway for Therapeutic Intervention of ASD and ADHD. P. Purkayastha, A. Malapati, P. Yogeeswari, D. Sriram. Curr. Med. Chem. 22, 1850-1859, 2015.
158. Pyridoxal-phosphate dependent mycobacterial cysteine synthases: Structure, mechanism and potential as drug targets. R. Schnell, D. Sriram, G. Schneider. Biochim. Biophys. Acta. 1854, 1175-1183, 2015.
159. New indole-isoxazolone derivatives: Synthesis, characterisation and in vitro SIRT1 inhibition studies. N. Panathur, N. Gokhale, U. Dalimba, P.V. Koushik, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. Lett. 25, 2768-2772, 2015.
160. Synthesis and biological evaluation of phaitanthrin congeners as anti-mycobacterial agents. A. Kamal, B.V. Reddy, B. Sridevi, A. Ravikumar, A. Venkateswarlu, G. Sravanthi, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. Lett. 25, 3867-3872, 2015.
161. Left hand side exploration of novel bacterial Topoisomerase inhibitors to improve selectivity against hERGBinding. P.S. Hameed, P. Manjrekar, A. Raichurkar, V. Shinde, J. Puttur, G. Shanbhag, M. Chinnapattu, V. Patil, S. Rudrapatana, S. Sharma, C.N. Kumar, R. Nandishaiah, P. Madhavapeddi, D. Sriram, S. Solapure, V.K. Sambandamurthy. ACS Med. Chem. Lett. 6, 741-746, 2015.
162. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics. Y. Nkizinkiko, B.V.S. Kumar, V.U. Jeankumar, T. Haikarainen, J. Koivunen, C. Madhuri, P. Yogeeswari, H. Venkannagari, E. Obaji, T. Pihlajaniemi, D. Sriram, L.Lehtiö. Bioorg. Med. Chem. 23, 4139-49, 2015.
163. Design of dual inhibitors of ROCK-I and NOX2 as potential leads for the treatment of neuroinflammationassociated with various neurological diseases including autism spectrum disorder. R. Alokam, S. Singhal, G.S. Srivathsav, S. Garigipati, S. Puppala, D. Sriram, P. Yogeeswari. Mol. Biosyst. 11, 607-617, 2015.
164. A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virusserotypes in cell culture. R. Raut, H. Beesetti, P. Tyagi, I. Khanna, S.K. Jain, V.U. Jeankumar, P. Yogeeswari, D. Sriram, S. Swaminathan. Virol. J. 12, 16, 2015.
165. Design and synthesis of novel carbazole tethered pyrrole derivatives as potent inhibitors of Mycobacterium tuberculosis. G. Surineni, P. Yogeeswari, D. Sriram, S. Kantevari. Bioorg. Med. Chem. Lett. 25, 485-491, 2015.
166. Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives. J. Ramprasad, N. Nayak, U. Dalimba, P. Yogeeswari, D. Sriram, S.K. Peethambar, R. Achur, H.S. Kumar. Eur. J. Med. Chem. 95, 49-63, 2015.
167. Synthesis and anti-mycobacterial activity of 2-chloronicotinaldehydes based novel 1H-1,2,3-triazolylbenzohydrazides. P. Suman, C. Dayakar, K. Rajkumar, B. Yashwanth, P. Yogeeswari, D. Sriram, J.V. Rao, B.C. Raju. Bioorg. Med. Chem. Lett. 25, 2390-2394, 2015.
168. Structure-based design of diverse inhibitors of Mycobacterium tuberculosis N-acetylglucosamine-1-phosphate uridyltransferase: combined molecular docking, dynamic simulation, and biological activity. V. Soni, P. S. Devara, D. Sriram,Nandicoori, OSDD Consortium, S. Kumar, V.K. Sriram,Nandicoori, P. Yogeeswari. J. Mol. Model. 21, 174, 2015.
169. Design of novel mycobacterium tuberculosis pantothenate synthetase inhibitors: Virtual screening, synthesis and in vitro biological activities. P. B. Devi, S. Jogula, A. P. Reddy, S. Saxena, J. P. S. Devi, D. Sriram, P. Yogeeswari. Mol. Inf. 34, 147-159, 2015.
170. Synthesis, molecular docking and anti-mycobacterial evaluation of new imidazo[1,2-a]pyridine-2-carboxamidederivatives. G. Jose, T.H.S. Kumara, G. Nagendrappa, H.B. Sowmya, D. Sriram, P. Yogeeswari, J.P.S. Devi, T.N.G. Row, A.A. Hosamani, P.S.S. Ganapathy, N.Chandrika, L.V. Narendra. Eur. J. Med. Chem. 89, 616-627, 2015.
171. Novel amide and sulphonamide derivatives of 6-(piperazin-1-yl)phenanthridine as potent Mycobacteriumtuberculosis H37Rv inhibitors. K.M. Naidu, H.N. Nagesh, M. Singh, D. Sriram, P. Yogeeswari, K.V.G.C Sekhar. Eur. J. Med. Chem. 92, 415-426, 2015.
172. Discovery of Rimonabant and its potential analogues as anti-TB drug candidates J. M. Gajbhiye, N. A. More, M. D. Patil, R. Ummanni, S. S. Kotapalli, P. Yogeeswari, D. Sriram, V. H. Masand. Med. Chem. Res. 24, 2960-297, 2015.
173. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors. M. Chandran, J. Renuka, G. S. Pedgaonkar, V. Asmitha, P. Yogeeswari, D. Sriram. Int. J. Mycobact., 4, 104–115, 2015.
174. Rational design, synthesis and evaluation of novel-substituted 1,2,3-triazolylmethyl carbazoles as potent inhibitors of Mycobacterium tuberculosis. G. Surineni, P. Yogeeswari, D. Sriram, S. Kantevari. Med. Chem. Res. 24, 1298-1309, 2015.
175. Effect of Feature Selection on Kinase Classification Models. P. Purkayastha, A. Rallapalli, N. L. Bhanu Murthy, A. Malapati, P. Yogeeswari, D. Sriram. Comput. Intell. Med. Inform. SpringerBriefs in App. Sci. Tech. 81-86, 2015.
176. Synthesis and evaluation of thiazolyl-1H-benzo[d]imidazole inhibitors of Mycobacterium tuberculosis inosine monophosphate dehydrogenase. K. Pissinate,Rostirolla, Pinheiro,S. Devara,Yogeeswari,Sriram,Basso,Machado,Santos,D.C. Pissinate,Rostirolla, Pinheiro,S. Devara,Yogeeswari,Sriram,Basso,Machado,Santos, L.M. Pissinate,Rostirolla, Pinheiro,S. Devara,Yogeeswari,Sriram,Basso,Machado,Santos, P. Pissinate,Rostirolla, Pinheiro,S. Devara,Yogeeswari,Sriram,Basso,Machado,Santos, P. Pissinate,Rostirolla, Pinheiro,S.Devara,Yogeeswari,Sriram,Basso,Machado,Santos, D. Pissinate,Rostirolla, Pinheiro,S. Devara,Yogeeswari,Sriram,Basso,Machado,Santos, L.A. Pissinate,Rostirolla, Pinheiro,S. Devara,Yogeeswari,Sriram,Basso,Machado,Santos, P. Pissinate,Rostirolla, Pinheiro,S. Devara,Yogeeswari,Sriram,Basso,Machado,Santos, D.S. Pissinate,Rostirolla, Pinheiro,S. Devara,Yogeeswari,Sriram,Basso,Machado,Santos, Pissinate,Rostirolla, Pinheiro,S. Devara,Yogeeswari,Sriram,Basso,Machado,Santos, J. Brazilian Chem. Soc. 26, 1357-1366, 2015.
177. Design, development, drug-likeness, and molecular docking studies of novel piperidin-4-imine derivatives asantitubercular agents. R. Revathi R, P.R. Venkatesha, K.S. Pai, G. Arunkumar, D. Sriram, S.G. Kini. Drug Des. Devel. Ther. 21, 3779-3787, 2015.
178. Medicinal chemistry updates and discovery strategies on potential therapeutic targets. B.V.S.S. Kumar, D. Sriram, P. Yogeeswari. Curr. Top. Med. Chem. 14, 1939, 2014.
179. Recent trends in library design and virtual screening in Medicinal Chemistry and Drug Discovery, B.V.S.S. Kumar, D. Sriram, P. Yogeeswari. Curr. Top. Med. Chem. 14, 1865, 2014.
180. Discovery of novel mycobacterial DNA gyrase B inhibitiors: In-silico and in-vitro biological evaluation. S. Saxena, J. Renuka, P. Yogeeswari, D. Sriram. Mol. Informatics, 33, 597-609, 2014.
181. Structure-guided design of novel thiazolidine derivatives as Mycobacterium tuberculosis pantothenate synthatase inhibitors. P. B. Devi, S. Ganesh, S. Saxena, A. Mallika, E. G. Salina, D. Sriram, P. Yogeeswari. ChemMedChem. 9, 2538-2547, 2014.
182. Synthesis and antitubercular evaluation of 2-iminothiazolidine-4-ones. S. Ganesh, C. Madhuri, J.P.S. Devi, R. Nallangi, P. Yogeeswari, D. Sriram. Eur. J. Chem. 5, 550-556, 2014.
183. Optimization and validation of Mycobacterium marinum-induced adult zebrafish model for evaluation of oral anti-tuberculosis drugs. J. P. S. Devi, H. S. A. Raju, P. Kulkarni, P. Yogeeswari, D. Sriram. Int. J. Mycobact. 3, 259-267, 2014 .
184. An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosisDNA GyrB inhibition. I. Reddy, K. Srihari, J. Renuka, K. S. Sree, A. Chuppala, V. U. Jeankumar, K. S. Babu, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem., 22, 6552-6563, 2014.
185. Synthesis of novel dispiropyrrolothiazoles by three-component 1,3-dipolar cycloaddition and evaluation of their antimycobacterial activity. S. Haddad, S. Boudriga, F. Porzio, A. Soldera, M. Askri, D. Sriram, P. Yogeeswari, M. Knorr, Y. Rousselin, M. Kubicki RSC Adv., 4, 59462-59471, 2014.
186. 2-Butyl-4-chloroimidazole based substituted piperazine-thiosemicarbazone hybrids as potent inhibitors of
     Mycobacterium tuberculosis. A. JallapallyD. AddlaP. YogeeswariD. SriramS. Kantevari, A. JallapallyD. AddlaP. YogeeswariD. SriramS. Kantevari, A. JallapallyD. AddlaP. YogeeswariD. SriramS. Kantevari, A. JallapallyD. AddlaP. YogeeswariD. SriramS. Kantevari, A. JallapallyD. AddlaP. YogeeswariD. SriramS. Kantevari. Bioorg. Med. Chem. Lett. 24, 5520-5524, 2014.
187. General and an efficient synthesis of benzoxazol-2(3H)-ones: Evolution of its anti-cancer and anti-mycobacterial activities. V. Vijayakumar, K. I. Reddy, A. Chuppala, K. S. Babu, M. Manisha, P. Yogeeswari, D. Sriram RSC Adv., 4, 59594-59602, 2014.
188. Mycobacterial DNA GyrB Inhibitors: Ligand Based Pharmacophore Modelling and In Vitro Enzyme Inhibition Studies. S. Saxena, J. Renuka, V.U. Jeankumar, P. Yogeeswari, D. Sriram. Curr. Top. Med. Chem. 14, 1990-2005, 2014.
189. Design, synthesis and screening studies of potent thiazol-2-amine derivatives as fibroblast growth factor receptor 1 inhibitors. B.V. Kumar, N. Lakshmi, M.R. Kumar, G. Rambabu, T.H. Manjashetty, K.M. Arunasree, D. Sriram, K. Ramkumar, N. Neamati, R. Dayam, J.A. Sarma. Curr. Top. Med. Chem. 14, 2031-2041, 2014.
190. Med. Chem. Commun.N-Arylalkylbenzo[d]thiazole-2-carboxamides as anti-mycobacterial agents: design, new methods of synthesis and biological evaluation. P. Shah, T.M. Dhameliya, R. Bansal, M. Nautiyal, D.N. Kommi, P.S. Jadhavar, J.P. S. Devi, P. Yogeeswari, D. Sriram, A.K. Chakraborti 245Med. Chem. Commun. 5, 1489-1495, 2014.
191. Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation. R.K. Mishra, R. Alokam, S.M. Singhal, G. Srivathsav, D. Sriram, N. Kaushik-Basu, D. Manvar, P. Yogeeswari. J. Chem. Inf. Model. 54, 2876-2886, 2014.
192. Salicylanilide Diethyl Phosphates as Potential Inhibitors of Some Mycobacterial Enzymes. M. Krátký, E. Novotná, S. Saxena, P. Yogeeswari, D. Sriram, M. Švarcová, J. Vinšová Scientific World Journal, Article ID 703053, 6 pages http://dx.doi.org/10.1155/2014/703053, 2014.
193. Structure-Guided Design of Thiazolidine Derivatives as Mycobacterium tuberculosis Pantothenate Synthetase Inhibitors. P.B. Devi, G. Samala, S. Saxena, M. Alvala, E.G. Salina, D. Sriram, P. Yogeeswari. ChemMedChem. 9, 2438-2547, 2014.
194. Design and development of novel Mycobacterium tuberculosis alanine dehydrogenase inhibitors. S. Saxena, G. Samala, P.B. Devi, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 92, 401-414, 2014.
195. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA. G.S. Pedgaonkar, V.U. Jeankumar, S. Saxena, P.B. Devi, J. Renuka, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. 22, 6134–6145, 2014.
196. Design, synthesis and antimycobacterial activity of various 3-(4-(substitutedsulfonyl)piperazin-1-yl)benzo[d]isoxazole derivatives. K.M. Naidu, A. Suresh, J. Subbalakshmi, D.Sriram, P. Yogeeswari, P. Raghavaiah, K.V.G.C. Sekhar. Eur. J. Med. Chem. 87, 71-78, 2014.
197. Anti-mycobacterial, cytotoxic activities of Knoevenagel and (E)-α,β-unsaturated esters and ketones from 2-chloronicotinaldehydes P. Suman, R.N. Rao, B.C. Raju, D. Sriram, P.V. Koushik. Med. Chem. Res. 23, 199-206, 2014.
198. Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis. G.S. Pedgaonkar, V.U. Jeankumar, S. Saxena, P.B. Devi, J. Renuka, P. Yogeeswari, D. Sriram Eur. J. Med. Chem, 86, 613-627, 2014.
199. Discovery of Novel Mycobacterial DNA Gyrase B Inhibitors: In Silico and In Vitro Biological Evaluation. S. Shalini, J. Renuka, P. Yogeeswari and D. Sriram Mol. Inf. 33, 597–609, 2014.
200. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis. J. Renuka, K.I. Reddy, K. Srihari, V.U. Jeankumar, M. Shravan, P. Yogeeswari, K.S. Babu, D. Sriram. Bioorg. Med. Chem. 22, 4924-4934, 2014.
201. Pharmacophore-based 3D-QSAR and molecular docking studies to identify new non-peptidic inhibitors of Cathepsin S. A.M. Babu, A.M. Chandra, D. Sriram, P. Yogeeswari. Curr. Med. Chem. 21, 1910-1921, 2014.
202. Gyrase ATPase Domain as an Antitubercular Drug Discovery Platform: Structure-Based Design and Lead Optimization of Nitrothiazolyl Carboxamide Analogues. V.U. Jeankumar, J. Renuka, S. Kotagiri, S. Saxena, S.S. Kakan, S. Yellanki, P. Kulkarni, P. Yogeeswari, D. Sriram.ChemMedChem. 9, 1850-1859, 2014.
203. Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: Pharmacophore mapping from known antibacterial leads. K.A. Bobesh, J. Renuka, V.U. Jeankumar, S.K. Shruti, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 85, 593- 604, 2014.
204. Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors. G. Samala, R. Nallangi, P.B. Devi, S. Saxena, R. Yadav, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. 22, 4223-4232, 2014.
205. Design, synthesis and antimycobacterial evaluation of 1-(4-(2-substitutedthiazol-4-yl)phenethyl)-4-(3-(4-substitutedpiperazin-1-yl)alkyl)piperazine hybrid analogues. H.N. Nagesh, A. Suresh, S.D.S.S. Sairam, D. Sriram, P. Yogeeswari, K.V.G.C Sekhar. Eur. J. Med. Chem. 84, 605-613, 2014.
206. New class of antitubercular compounds: Synthesis and antitubercular activity of 4-substituted pyrrolo[2,3-c]quinolines. M. Akula, P. Yogeeswari, D. Sriram, A. Bhattacharya, Monatschefte fur chemie , 145, 811-819, 2014.
207. Investigating structure–activity relationship and mechanism of action of antitubercular 1-(4-chlorophenyl)-4-(4-hydroxy-3-methoxy-5-nitrobenzylidene) pyrazolidine-3,5-dione [CD59]. G. Samala, S.S. Kakan, R. Nallangi, P.B. Devi, S. Saxena, P. Yogeeswari, D. Sriram Int. J. Mycobact. 3, 117-126, 2014.
208. 
     Design, synthesis and anti-mycobacterial activity of 1,2,3,5-tetrasubstituted pyrrolyl-N-acetic acid derivatives. L.R. Pagadala, L.D. Mukkara, S. Singireddi, A. Singh, V.R. Thummaluru, P.S. Jagarlamudi, R.S. Guttala, P. Yogeeswari, D. Sriram, S.M. Upadhyayula, R. Ummanni, V.S. Basireddy, N. Ravirala. Eur. J. Med. Chem. 84, 118-126, 2014.
209. Combined inhibition of PDE4 and PI3Kδ modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease. S.S. Dinavahi, S. Nyayapathy, P. Yogeeswari, D. Sriram, S. Viswanadha. Drug Res. 64, 214-219, 2014.
210. Synthesis and antimycobacterial activities of some new thiazolylhydrazone derivatives. K. Ozadali, O.U. Tan, P. Yogeeswari, D. Sriram, A. Balkan. Bioorg. Med. Chem. Lett. 24, 1695-1697, 2014.
211. Identification and structure-activity relationship study of carvacrol derivatives as Mycobacterium tuberculosis chorismate mutase inhibitors. R. Alokam, V.U. Jeankumar, S.S. Matikonda, S. Peddi, M. Alvala, P. Yogeeswari, D. Sriram. J. Enzyme Inhib. Med. Chem. 29, 547-554, 2014.
212. Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads. V.U. Jeankumar, J. Renuka, V.K. Pulla, V. Soni, P. S. Devara, M. Shravan, R. Medishetti, P. Kulkarni, P. Yogeeswari, D. Sriram. Int. J. Antimicrob. Agents. 43, 269-278, 2014.
213. Synthesis and evaluation of anti-tubercular activity of 6-(4-substitutedpiperazin-1-yl) phenanthridine analogues. H.N. Nagesh, N. Suresh, K.M. Naidu, B. Arun, D. Sriram, P. Yogeeswari, K.V.C. Sekhar. Eur. J. Med. Chem. 74, 333-339, 2014.
214. 3D QSAR analysis of 2-(substituted aryl)-thiazolidine-4-carboxamides as potent antitubercular agents. K.P. Nagasree, M.M. Kumar, Y.R. Prasad, D. Sriram, P. Yogeeswari. Curr. Comput. Aided Drug. Des. 10, 274-281, 2014.
215. Structure-based drug design of small molecule SIRT1 modulators to treat cancer and metabolic disorders. V.K. Pulla, M. Alvala, D.S. Sriram, S. Viswanadha, D. Sriram, P. Yogeeswari. J. Mol. Graph. Model. 52, 46-56, 2014.
216. Development of antimycobacterial tetrahydrothieno[2,3-c]pyridine-3-carboxamides and hexahydrocycloocta[b]thiophene-3-carboxamides: Molecular modification from known antimycobacterial lead. R. Nallangi, G. Samala, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 76, 110-117, 2014.
217. Discovery and structure optimization of a series of isatin derivatives as Mycobacterium tuberculosis chorismate mutase inhibitors. V.U. Jeankumar, R. Alokam, P. S. Devara, S.S. Matikonda, S. Peddi, S. Sahithi, M. Alvala, P. Yogeeswari, D. Sriram. Chem. Biol. Drug. Des. 83, 498-506, 2014.
218. Design, synthesis and evaluation of 1,2,3-triazole-adamantylacetamide hybrids as potent inhibitors of Mycobacterium tuberculosis. D. Addla, A. Jallapally, D. Gurram, P. Yogeeswari, D. Sriram, S. Kantevari. Bioorg Med Chem Lett. 24, 1974-1979, 2014.
219. Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing. P.S. Hameed, A. Raichurkar, P. Madhavapeddi, S. Menasinakai, S. Sharma, P. Kaur, R. Nandishaiah, V. Panduga, J. Reddy, V.K. Sambandamurthy, D. Sriram ACS Med Chem Lett. 5, 820-825, 2014.
220. Multiple e-Pharmacophore Modeling, 3D-QSAR, and High-Throughput Virtual Screening of Hepatitis C Virus NS5B Polymerase Inhibitors. P. J. Therese, D. Manvar, S. Kondepudi, M. B. Battu, D. Sriram, A. Basu, P. Yogeeswari, N. K. Basu. J. Chem. Inf. Model. 54, 539-552, .
221. Synthesis and evaluation of anti-tubercular activity of 6-(4-substitutedpiperazin-1-yl) phenanthridine analogues. H. N. Nagesh, N. Suresh, K. M. Naidu, B. Arun, J. P. Sridevi, D. Sriram, P Yogeeswari, K. V. G. C. Sekhar, Eur. J. Med. Chem. 74, 333-339, 2014.
222. Development of novel tetrahydrothieno[2,3-c]pyridine-3-carboxamide based Mycobacterium tuberculosis pantothenate synthetase inhibitors: Molecular hybridization from known antimycobacterial leads. G Samala, P. B. Devi, R Nallangi, S Saxena, P Yogeeswari, D. Sriram. Bioorg. Med. Chem. 22, 1938-1947, 2014.
223. Development of antimycobacterial tetrahydrothieno[2,3-c]pyridine-3-carboxamides and hexahydrocycloocta[b]thiophene-3-carboxamides: Molecular modification from known antimycobacterial lead. R. Nallangi, G. Samala, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 76, 110-117, 2014.
224. Synthesis, antibacterial, antifungal and antitubercular activities of N-pyrazolylbenzamide derivatives. R. Kulkarni, V. Kumar, H. Babu, K. Kumar, N. Gaddam, A. Fatima, S. Muvvala, D.V. Bhikshapathi, D. Sriram, A. Garlapati, J. Vishnav, P. Gurav. Med. Chem. 10, 220-227, 2014.
225. Future directions in the treatment of neuropathic pain: a review on various therapeutic targets. M. Gangadhar, R.K. Mishra, D. Sriram, P. Yogeeswari. CNS Neurol. Disord. Drug Targets. 13, 63-81, 2014.
226. Synthesis, antitubercular and anticancer activity of new Baylis–Hillman adduct-derived N-cinnamyl-substituted isatin derivatives. S. B. Kumar, M. Ravinder, G. Kishore, V. J. Rao, P. Yogeeswari, D. Sriram. Med. Chem. Res. 23, 1934-1940, 2014.
227. Identification of novel inhibitors against Mycobacterium tuberculosis l-alanine dehydrogenase (MTB-AlaDH) through structure-based virtual screening. S. Saxena, P. B. Devi, V. Soni, P. Yogeeswari, D. Sriram. J. Mol. Graph. Mod. 47, 37-43, 2014.
228. Rational design, synthesis and antitubercular evaluation of novel 2-(trifluoromethyl)phenothiazine-[1,2,3]triazole hybrids. D. Addla, A. Jallapally, D. Gurram, P. Yogeeswari, D. Sriram, K. Srinivas. Bioorg. Med. Chem. Lett. 24, 233-236, 2014.
229. Rational design and synthesis of novel dibenzo[b,d]furan-1,2,3-triazole conjugates as potent inhibitors of Mycobacterium tuberculosis. T. Yempala, P. Yogeeswari, D. Sriram, K. Srinivas. Eur. J. Med. Chem. 71, 160-167, 2014.
230. Discovery of tetrahydropyrido[4,3-d]pyrimidine derivatives for the treatment of neuropathic pain M. Sharma, V. Deekshith, A. Semwal, D. Sriram, P. Yogeeswari. Bioorg. Chem. 52, 69–76, 2014.
231. Design, synthesis and evaluation of 6-(4-((substituted-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenanthridine analogues as antimycobacterial agents. H.N. Nagesh, K.M. Naidu, D.H. Rao, D. Sriram, P. Yogeeswari, K.V.C. Sekhar. Bioorg. Med. Chem. Lett. 23, 6805-6810, 2013.
232. Thiazole-aminopiperidine hybrid analogues: Design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors. V.U. Jeankumar, J. Renuka, P. Santosh, V. Soni, P. S. Devara, P. Yogeeswari, D. Sriram. Eur J Med Chem. 70, 143-153, 2013.
233. Development of 3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel Mycobacterium tuberculosis pantothenate synthetase inhibitors. G. Samala, P.B. Devi, R. Nallangi, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 69, 356-364, 2013.
234. Relationship between plasma levels and the anti-neuropathic pain effect of Lamotrigine in rat model. H Veesam, P.R. Avula, S.R. Challa, G. Matharasala, P. Yogeeswari, D. Sriram J. Pharm. Res. 6, 780-784, 2013.
235. Identification and characterization of novel indole based small molecules as anticancer agents through SIRT1 inhibition. N. Panathur, U. Dalimba, P. V. Koushik, M. Alvala, P. Yogeeswari, D. Sriram, V. Kumar. Eur. J. Med. Chem. 69, 125–138, 2013.
236. Structure-Guided Design of Novel Thiazolidine Inhibitors of O-Acetyl Serine Sulfhydrylase from Mycobacterium tuberculosis. O. Poyraz, V.U. Jeankumar, S. Saxena, R. Schnell, M. Haraldsson, P. Yogeeswari, D. Sriram, G. Schneider G. J. Med. Chem. 56, 6457-6466, 2013.
237. Design, synthesis and antitubercular evaluation of novel 2-substituted-3H-benzofuro benzofurans via palladium-copper catalysed Sonagashira coupling reaction. T. Yempala, P. Yogeeswari, D. Sriram, S. Kantevari. Bioorg. Med. Chem. Lett. 23, 5393-5396, 2013.
238. Discovery of novel tetrahydro-pyrazolo [4,3-c] pyridines for the treatment of neuropathic pain: Synthesis and neuropharmacology. P. Yogeeswari, M. Sharma, G. Samala, M. Gangadhar, S. Karthick, S. Mallipeddi, A. Semwal, D. Sriram. Eur J Med Chem. 66, 211-220, 2013.
239. Scientific evidence for traditional claim of anti-obesity activity of Tecomella undulata bark R. Alvala, M. Alvala, V. Sama, D.Sriram , J. V. Ullas, M.B. Reddy. J. Ethnopharmacol. 148, 441-448, 2013
240. Potential role of rho kinase inhibitors in combating diabetes-related complications including diabetic neuropathy-a review. R.K. Mishra, R. Alokam, D. Sriram, P. Yogeeswari. Curr Diabetes Rev. 9, 249-266, 2013.
241. Multiple e-Pharmacophore Modeling Combined with High- Throughput Virtual Screening and Docking to Identify Potential Inhibitors of β-Secretase (BACE1) R. Palakurti, D.Sriram, P.Yogeeswari, R. Vadrevu. Mol. Inf. 32, 385 – 398, 2013.
242. Discovery of novel inhibitors targeting the Mycobacterium tuberculosis O-acetylserine sulfhydrylase (CysK1) using virtual high-throughput screening. V. U. Jeankumar, Ö. Poyraz, S. Saxena, R. Schnell, P. Yogeeswari, G. Schneider, D.Sriram Bioorg. Med. Chem. Lett. 23, 1182-1186, 2013.
243. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach. U.C. KumarB.V.S.S. KMahmoodD. SK. SahuPulakanamBallellGomezMalik JarpFuture Med Chem., KumarB.V.S.S. KMahmoodD. SK. SahuPulakanamBallellGomezMalik JarpFuture Med Chem.umar, S. KumarB.V.S.S. KMahmoodD. SK. SahuPulakanamBallellGomezMalik JarpFuture Med Chem., KumarB.V.S.S. KMahmoodD. SK. SahuPulakanamBallellGomezMalik JarpFuture Med Chem.riram, P. KumarB.V.S.S. KMahmoodD. SK. SahuPulakanamBallellGomezMalik JarpFuture Med Chem., S. KumarB.V.S.S. KMahmoodD. SK. SahuPulakanamBallellGomezMalik JarpFuture Med Chem., L. KumarB.V.S.S. KMahmoodD. SK. SahuPulakanamBallellGomezMalik JarpFuture Med Chem., D.A. KumarB.V.S.S. KMahmoodD. SK. SahuPulakanamBallellGomezMalik JarpFuture Med Chem., S. KumarB.V.S.S. KMahmoodD. SK. SahuPulakanamBallellGomezMalik JarpFuture Med Chem., S. KumarB.V.S.S. KMahmoodD. SK. SahuPulakanamBallellGomezMalik JarpFuture Med Chem.. KumarB.V.S.S. KMahmoodD. SK. SahuPulakanamBallellGomezMalik JarpFuture Med Chem. 5, 249-59, 2013.
244. Enhanced ranking of PknB Inhibitors using data fusion methods. A. Seal, P. Yogeeswari, D. Sriram, OSDD Consortium, D.J. Wild. J. Cheminform. 2013 Jan 14;5(1):2. doi: 10.1186/1758-2946-5-2.
245. Synthesis and antitubercular activity of amino alcohol fused spirochromone conjugates M. Mujahid, R.G. Gonnade, P. Yogeeswari, D. Sriram, M. Muthukrishnan . Bioorg. Med. Chem. Lett. 23, 1416-1419, 2013.
246. Synthesis, Antimycobacterial, Antiviral, Antimicrobial Activity and QSAR Studies of N2-acyl Isonicotinic Acid Hydrazide Derivatives. V. Judge, B. Narasimhan, M. Ahuja, D. Sriram, P. Yogeeswari, E. De Clercq, C. Pannecouque, J. Balzarini. Med. Chem. 9, 53-76, 2013.
247. Synthesis and preliminary screening of O-β-D-galactopyranosides as potential mimic of UDP-Gal p against mycobacterium tuberculosis. G. Mugunthan, D. Sriram, P. Yogeeswari, K.P.R. Kartha. J. Carbohyd. Chem. 31, 553-570, 2012.
248. Study of Pharmacokinetics and Tissue Distribution of BITS-17 in Rat Plasma and Tissue Homogenate Using a Validated LC Method. A. V. Ramani, V. L. Indira, S.Vani, S. Gill, P. Yogeeswari, D. Sriram J. Bioanal. Biomed. 4, 079-084, 2012.
249. Development of 5-nitrothiazole derivatives: Identification of leads against both replicative and latent Mycobacterium tuberculosis. V. U. Jeankumar, M. Chandrana, G. Samala, M. Alvala, P. V. Koushika, P. Yogeeswari, E. G. Salina, D. Sriram. Bioorg. Med. Chem. Lett. 22, 7414–7417, 2012
250. Molecular hybridization of bioactives: Synthesis and antitubercular evaluation of novel dibenzofuran embodied homoisoflavonoids via Baylis–Hillman reaction T. Yempala, D. Sriram, P. Yogeeswari, S. Kantevaria. Bioorg. Med. Chem. Lett. 22, 7426–7430, 2012.
251. Synthesis, antimycobacterial, antiviral, antimicrobial activity and QSAR studies of Isonicotinic acid-1-(substituted phenyl)-ethylidene/ cycloheptylidene hydrazides. R. Narang, B. Narasimhan, S. Sharma, D. Sriram, P. Yogeeswari, E. De Clercq, C. Pannecouque, J. Balzarini, Medicinal Chemistry Research 21, 1935-1952, 2012.
252. Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of nicotinic acid benzylidene hydrazide derivatives. R. Narang, B. Narasimhan, S. Sharma, D. Sriram, P. Yogeeswari, E. De Clercq, C. Pannecouque, J. Balzarini, Medicinal Chemistry Research 21, 1557-1576, 2012.
     Isonicotinic acid hydrazide derivatives: synthesis, antimicrobial activity, and QSAR studies. V. Judge, B. Narasimhan, M. Ahuja, D. Sriram, P. Yogeeswari, E. De Clercq, C. Pannecouque, J. Balzarini. Medicinal Chemistry Research , 21, 1451-1470, 2012.
253. Combination of N-methylisatin-β-thiosemicarbazone derivative (SCH16) with ribavirin and mycophenolic acid potentiates the antiviral activity of SCH16 against Japanese encephalitis virus in vitro. L. Sebastian, A. Desai, P. Yogeeswari, D. Sriram, S.N Madhusudana, V. Ravi. Lett. Appl. Microbiol. 55, 234-239, 2012.
254. Novel Piperazinyl Derivatives with Anti-Hyperalgesic, Anti-Allodynic and Anti-Inflammatory activities Useful for the Treatment of Neuropathic Pain. M. Sharma, S.S Dash, G. Matharasala, V. Deekshith, D. Sriram, P. Yogeeswari. Antiinflamm. Antiallergy Agents Med. Chem. 11, 182-190, 2012.
255. Discovery of novel 1,2,4-triazol-5-ones as tumor necrosis factor-alpha inhibitors for the treatment of neuropathic pain. M. Sharma, S. Garigipati, B. Kundu, D. Vanamala, A. Semwal, D. Sriram, P. Yogeeswari. Chem. Biol. Drug Des. 80, 961-970, 2012.
256. Synthesis and antimycobacterial activities of some new N-acylhydrazone and thiosemicarbazide derivatives of 6-methyl-4,5-dihydropyridazin-3(2H)-one. O. U. Tan, K. Ozadali, P. Yogeeswari, D. Sriram, A. Balkan. Med. Chem. Res. 21, 2388-2394, 2012.
257. Design, synthesis and evaluation of small molecule reactive oxygen species generators as selective Mycobacterium tuberculosis inhibitors. A.T. Dharmaraja, M. Alvala, D. Sriram, P. Yogeeswari, H. Chakrapani H. Chem. Commun. (Camb). 48, 10325-10327, 2012.
258. Can targeting SIRT-1 to treat type 2 diabetes be a good strategy? A review. V.K. Pulla, M.B. Battu, M. Alvala, D. Sriram, P. Yogeeswari. Expert Opin. Ther. Targets. 16, 819-832, 2012.
259. Synthesis and in vitro antitubercular activity of 4-aryl/alkylsulfonylmethylcoumarins as inhibitors of Mycobacterium tuberculosis. M. Jeyachandran, P. Ramesh, D. Sriram, P. Senthilkumar, P. Yogeeswari. Bioorg. Med. Chem. Lett. 22, 4807-4809, 2012.
260. GABA derivatives for the treatment of epilepsy and neuropathic pain: A synthetic integration of GABA in 1, 2, 4–Triazolo–2H–one nucleus. P. Yogeeswari, S. K. Patel, I. V. Reddy, A. Semwal, M. Sharma, M. Gangadhar , M. S. Sai , D. Sriram. Biomed. & Aging Pathol. 2, 31-40, 2012.
261. A solvent free, four-component synthesis and 1,3-dipolar cycloaddition of 4(H)-pyrans with nitrile oxides: Synthesis and discovery of antimycobacterial activity of enantiomerically pure 1,2,4-oxadiazoles. A.I. Almansour, R. Suresh Kumar, N. Arumugam, D. Sriram. Eur. J. Med. Chem. 53, 416-423, 2012.
262. Synthesis and antimycobacterial activity of prodrugs of sulfur dioxide (SO2). S.R. Malwal, D. Sriram, P. Yogeeswari, H. Chakrapani. Bioorg. Med. Chem. Lett. 22, 3603-3606, 2012.
263. Design, Synthesis, and Structure-Activity Correlations of Novel Dibenzo[b,d]furan, Dibenzo[b,d]thiophene, and N-Methylcarbazole Clubbed 1,2,3-Triazoles as Potent Inhibitors of Mycobacterium tuberculosis. S.R. Patpi, L. Pulipati, P. Yogeeswari, D. Sriram, N. Jain, B. Sridhar, R. Murthy, A.T. Devi, S.V. Kalivendi, S. Kantevari. J. Med. Chem. 55, 3911-3922, 2012.
264. Synthesis of highly potent novel anti-tubercular isoniazid analogues with preliminary pharmacokinetic evaluation. A.V. Ramani, A. Monika, V.L Indira, G. Karyavardhi, J. Venkatesh, V.U. Jeankumar, T.H. Manjashetty, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. Lett. 22, 2764-2767, 2012.
265. Novel acridinedione derivatives: Design, synthesis, SIRT1 enzyme and tumor cell growth inhibition studies. A. Mallika, B. Shubhmita, A. Ravi, V. U. Jeankumar, H.M. Thimmappa, P. Yogeeswari, D. Sriram, Bioorg. Med. Chem. Lett. 22, 3256–3260, 2012.
266. Antitubercular activities of novel diallyl/dibenzyl thiosemicarbazones endowed with high activity toward multi-drug resistant tuberculosis. D. Sriram, D. Banerjee, T. S. T. V. N. Varuna , M. Sankar, P. Yogeeswari. Med. Chem. Res. 21, 810-815, 2012.
267. Camphorsulfonic acid catalysed facile tandem double Friedlander annulation protocol for the synthesis of phenoxy linked bisquinoline derivatives and discovery of antitubercular agents. N. Paul, M. Murugavel, S. Muthusubramanian, D. Sriram. Bioorg. Med. Chem. Lett., 22, 1643-1648 2012.
268. Design, synthesis, and evaluation of thiol-activated sources of sulfur dioxide (SO₂) as antimycobacterial agents. S.R. Malwal, D. Sriram, P. Yogeeswari, V.B. Konkimalla, H. Chakrapani. J. Med. Chem. 55, 553-557, 2012.
269. Nicotinic acid benzylidene/phenyl-ethylidene hydrazides: synthesis, antimicrobial evaluation and QSAR studies. R. Narang, B. Narasimhan, S. Sharma, D. Sriram, P.Yogeeswari, E. De Clercq, C. Pannecouque J. Balzarini. Lett. Drug Des. Dis. 8, 733-749, 2011.
270. Synthesis and screening of galactose-linked nitroimidazoles and triazoles against Mycobacterium tuberculosis. G. Mugunthan, K. Ramakrishna, D. Sriram, P. Yogeeswari, R. K.P. Kartha. Eur. J. Med. Chem. 46, 4725-4732, 2011.
271. Synthesis, antimicrobial and antimycobacterial evaluation of [2-(substituted phenyl)-imidazol-1-yl]-pyridin-3-yl-methanones. D. Sharma, B. Narasimhan, P. Kumar, P. Yogeeswari, D. Sriram J. Enz. Inhib. Med. Chem. 26, 720-727, 2011.
272.  
273. Exploring aryl thiazolidine carboxamides as a new class of antimycobacterials D. Sriram, P. Yogeeswari, J.T. Patrisha, P. Senthilkumar, P. N. Kurre, and Y. R.Prasad Pharmacologyonline 1, 185-195, 2011.
274. Efficient synthesis and in vitro antitubercular activity of 1,2,3-triazoles as inhibitors of Mycobacterium tuberculosis. P. Shanmugavelan, S. Nagarajan, M. Sathishkumar, A. Ponnuswamy, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. Lett. 21, 7273-7276, 2011.
275. A facile synthesis of carbocycle-fused mono and bis-1,2,3-selenadiazoles and their antimicrobial and antimycobacterial studies. S. Chitra, N. Paul, S. Muthusubramanian, P. Manisankar, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 46, 5465-5472, 2011.
276. Synthetic analogues of mycobacterial arabinogalactan linkage-disaccharide part II: synthesis and preliminary screening of lipophilic O-alkyl glycosides. G. Mugunthan, D. Sriram, P. Yogeeswari, K.P. Kartha. Carbohydr. Res. 346, 2401-2405, 2011.
277. Synthesis of 3-heteroarylthioquinoline derivatives and their in vitro antituberculosis and cytotoxicity studies. S. Chitra, N. Paul, S. Muthusubramanian, P. Manisankar, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 46, 4897-4903, 2011.
278. Synthesis of various 3-nitropropionamides as Mycobacterium tuberculosis isocitrate lyase inhibitor. D. Sriram, P. Yogeeswari, S. Methuku, D.R. Vyas, P. Senthilkumar, M. Alvala, V.U. Jeankumar. Bioorg. Med. Chem. Lett. 21, 5149-5154, 2011.
279. A facile four-component sequential protocol in the expedient synthesis of novel 2-aryl-5-methyl-2,3-dihydro-1H-3-pyrazolones in water and their antitubercular evaluation. P. Gunasekaran, S. Perumal, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 46, 4530-4536, 2011.
280. Synthesis and antitubercular evaluation of novel dibenzo[b,d]furan and 9-methyl-9H-carbazole derived hexahydro-2H-pyrano[3,2-c]quinolines via Povarov reaction. S. Kantevari, T. Yempala, G. Surineni, B. Sridhar, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 46, 4827-4833, 2011.
281. Synthesis and biological evaluation of sugar-derived chiral nitroimidazoles as potential antimycobacterial agents. G. Mugunthan, D. Sriram, P. Yogeeswari, R.K.P. Kartha. Carbohyd. Res. 346, 1760-1766, 2011.
282. Facile Diversity-Oriented Synthesis and Antitubercular Evaluation of Novel Aryl and Heteroaryl Tethered Pyridines and Dihydro-6H-quinolin-5-ones derived via Variants of the Bohlmann-Rahtz Reaction. K. Srinivas, S.R. Patpi, D. Addla, S.R Putapatri, B. Sridhar, P. Yogeeswari, D. Sriram. ACS Comb Sci. 13, 427-435, 2011.
283. Antimycobacterial activity of spirooxindolo-pyrrolidine, pyrrolizine and pyrrolothiazole hybrids obtained by a three-component regio- and stereoselective 1,3-dipolar cycloaddition S. M. Rajesh, S. Perumal, J. C. Menéndez, P. Yogeeswari and D.Sriram Med. Chem. Commun., 2, 626-630, 2011.
284. Synthesis and antitubercular evaluation of amidoalkyl dibenzofuranols and 1H-benzo[2,3]benzofuro[4,5-e][1,3]oxazin-3(2H)-ones. S. Kantevari, T. Yempala, P. Yogeeswari, D. Sriram, B. Sridhar. Bioorg. Med. Chem. Lett. 21, 4316-4319, 2011.
285. Synthesis and screening of (E)-1-(β-d-galactopyranosyl)-4-(aryl)but-3-ene-2-one against Mycobacterium tuberculosis. G.Mugunthan, K. Ramakrishna, D. Sriram, P. Yogeeswari, R.K.P. Kartha. Bioorg. Med. Chem. Lett. 21, 3947-3950, 2011.
286. Discovery of molecules for the treatment of neuropathic pain: Synthesis, antiallodynic and antihyperalgesic activities of 5-(4-nitrophenyl)furoic-2-acid hydrazones. P. Yogeeswari, N. Menon, A. Semwal, M. Arjun, D. Sriram Eur. J. Med. Chem. 46, 2964-2970, 2011.
287. Antimycobacterial activity of novel 1,2,4-oxadiazole-pyranopyridine/chromene hybrids generated by chemoselective 1,3-dipolar cycloadditions of nitrile oxides. R. Ranjith Kumar, S. Perumal, JC, Menéndez, P. Yogeeswari, D. Sriram Bioorg. Med. Chem. 19, 3444-3450, 2011.
288. Synthesis and antimycobacterial activity of highly functionalized tetrahydro-4(1H)-pyridinones. V.P. Raja, S. Perumal, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. Lett. 21, 3881-3884, 2011.
289. A green expedient synthesis of pyridopyrimidine-2-thiones and their antitubercular activity. Rajesh SM, Kumar RS, Libertsen LA, Perumal S, Yogeeswari P, Sriram D. Bioorg. Med. Chem. Lett., 21, 3012-3016, 2011.
290. Microwave assisted one-pot synthesis of highly potent novel isoniazid analogues. T.H Manjashetty, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. Lett., 21, 2125-2128, 2011.
291. Synthesis and antitubercular evaluation of novel substituted aryl and thiophenyl tethered dihydro-6H-quinolin-5-ones. S. Kantevari, S.R. Patpi, B. Sridhar, P. Yogeeswari, D. Sriram Bioorg. Med. Chem. Lett. 21, 1214-1217, 2011.
292. Syntheses and biological evaluation of new triazole-spirochromone conjugates as inhibitors of Mycobacterium tuberculosis M. Muthukrishnan, M. Mujahid, P. Yogeeswari, D. Sriram Tetrahedron Letters 52, 2387-2389, 2011.
293. Novel isatinyl derivatives as potential molecule in the crusade against HIV-TB co-infection. D. Sriram, D. Banerjee, P. Yogeeswari, P. Bhat, A. Thomas. Eur. J. Med. Chem. 46, 106-121, 2011.
294. Synthesis, structure–activity relationship of novel substituted 4H-chromen-1,2,3,4-tetrahydropyrimidine-5-carboxylates as potential anti-mycobacterial and anticancer agents B. China Raju, R. Nageswara Rao, P. Suman, P. Yogeeswari, D. Sriram, Thokhir Basha Shaik, Shasi Vardhan Kalivendi Bioorg. Med. Chem. Lett., 21, 2855-2859, 2011.
295. A facile 1,3-dipolar cycloaddition of azomethine ylides to 2-arylidene-1,3-indanediones: synthesis of dispiro-oxindolylpyrrolothiazoles and their antimycobacterial evaluation. S. U. Maheswari, K. Balamurugan, S. Perumal, P. Yogeeswari, D. Sriram Bioorg. Med. Chem. Lett. 20, 7278-7282, 2010.
296. Facile three-component domino reactions in the regio-selective synthesis and antimycobacterial evaluation of novel indolizines and pyrrolo[2,1-a]isoquinolines" S. Muthusaravanan, S. Perumal, P. Yogeeswari, D. Sriram Tetrahedron Letters 51, 6439-6443, 2010.
297. A regio- and stereoselective 1,3-dipolar cycloaddition for the synthesis of novel spiropyrrolothiazolyloxindoles and their antitubercular evaluation. P. Prasanna, K. Balamurugan, S. Perumal, P. Yogeeswari, D. Sriram Eur. J. Med. Chem. 45, 5653-5661, 2010.
298. 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: Synthesis and antimycobacterial activities. D. Sriram, P. Yogeeswari, P. Senthilkumar, G. Naidu J. Enz. Inhib. Med. Chem., 25, 765-772, 2010.
299. Synthesis and antitubercular activities of substituted benzoic acid N'-(substituted benzylidene/furan-2-ylmethylene)-N-(pyridine-3-carbonyl)-hydrazides. P. Kumar, B. Narasimhan, D. Sharma, P. Yogeeswari, D. Sriram Eur. J. Med. Chem. 45, 6085-6089, 2010.
300. Pyrazole derivatives from azines of substituted phenacyl aryl/cyclohexyl sulfides and their antimycobacterial activity. R. Manikannan, S. Muthusubramanian, P. Yogeeswari, and D. Sriram Bioorg. Med. Chem. Lett. 20, 6920-6924, 2010.
301. 1,3-Dipolar cycloaddition of nitrile oxides to (R)-1-(1-phenylethyl)-3,5-bis[(E)-arylmethylidene]tetrahydro-4(1H)-pyridinones: Synthesis and antimycobacterial evaluation of novel enantiomerically pure di- and trispiroheterocycles. R.S. Kumar, S.M. Rajesh, S. Perumal, P. Yogeeswari, D. Sriram. Terahedron Asymmtry, 21, 1315-1327, 2010.
302. Antiallodynic and antihyperalgesic activities of anticonvulsant gaba derivatives in both sciatic nerve and spinal nerve ligation models of neuropathic pain P. Yogeeswaria, A. Semwal, D. Sriram, J.V. Ragavendran, N. Sreevatsan, S. Monika Pharmacologyonline, 2, 634-647, 2010.
303. 5-Nitro-2-furoic acid hydrazones: Design, synthesis and in-vitro antimycobacterial evaluation against log and starved phase cultures. D. Sriram, P. Yogeeswari, D. R.i K. Vyas, P. Senthilkumar, P. Bhat, M. Srividya. Bioorg. Med. Chem. Lett. 20, 4313-4316, 2010.
304. Aromatic Amino Analogues of Artemisinin: Synthesis and In-vivo Antimalarial Activity. D. Sriram, R. V. Devakaram, M. Dinakaran, P. Yogeeswari. Med. Chem. Res. 19, 524-532, 2010.
305. A facile synthesis and discovery of highly functionalized tetrahydropyridines and pyridines as antimycobacterial agents. R. S. Kumar, S. M. Rajesh, S. Perumal, D. Banerjee, P. Yogeeswari and D. Sriram. Chem. Pharm. Bull. 58, 602-610, 2010.
306. Selective one-pot multicomponent synthesis and antitubercular evaluation of 5-(aryl/cyclohexylsulfanyl)-2-alkoxy-4,6-diarylnicotinonitriles. R. Manikannan, S. Muthusubramanian, P. Yogeeswari and D. Sriram. Bioorg. Med. Chem. Lett., 20, 3352-3355, 2010.
307. Synthesis and antimycobacterial evaluation of novel phthalazin-4-ylacetamides against log- and starved phase cultures. D. Sriram, P.Yogeeswari, P. Senthilkumar, D. Sangaraju, R. Nelli, D. Banerjee, P. Bhat, T.H Manjashetty. Chem. Biol. & Drug Design, 75, 381-391, 2010.
308. Effectiveness of antiepileptic GABA analogues for the treatment of neuropathic pain P. Yogeeswari, J. V. Ragavendran, D. Sriram, A. Priyanka, S. Ganguly, A. Sunil Kumar Reddy, Arvind Semwal Pharmacologyonline 1, 575-590, 2010.
309. A microwave-assisted, facile, regioselective Friedländer synthesis and antitubercular evaluation of 2,9-diaryl-2,3-dihydrothieno-[3,2-b]quinolines. K. Balamurugan, V. Jeyachandran, S. Perumal, T. H. Manjashetty, P. Yogeeswari, D. Sriram Eur. J. Med. Chem. 45, 682-688, 2010.
310. 5-Nitrothiazolylthiosemicarbazones: Synthesis and antimycobacterial evaluation against tubercular and non-tubercular mycobacterial species. D. Sriram, P. Yogeeswari, P. Senthilkumar, S. Dewakar. J. Enzyme Inhib. Med. Chem., 25, 105-110, 2010.
311. A highly atom economic, chemo-, regio- and stereoselective synthesis and evaluation of spiro-pyrrolothiazolesas antitubercular agents. S. V. Karthikeyan, B. D. Bala, V. P. A. Raja, S. Perumal, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. Lett., 20, 350-353, 2010.
312. Discovery of Newer Antitubercular 2,10-Dihydro-4aH-chromeno[3,2-c]pyridin-3-yl Derivatives. D. Sriram, P. Yogeeswari, M. Dinakaran, D. Banerjee, P. Bhat, S. Gadhwal Eur. J. Med. Chem. 45, 120-123, 2010.
313. 1,3-Dipolar cycloaddition of C-aryl-N-phenylnitrones to (R)-1-(1-phenylethyl)-3-[(E)-arylmethylidene]tetrahydro-4(1H)-pyridinones: Synthesis and antimycobacterial evaluation of enantiomerically pure spiroisoxazolidines. R. S. Kumar, S. Perumal, K. A. Shetty, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 45, 124-133, 2010.
314. Discovery of Isatinimino Derivatives as New Leads for Neuropathic Pain Treatment: An Isomeric Modification Approach. A. Semwal, P. Yogeeswari, J. V. Ragavendran, D. Sriram, J. Stables Int. J. Drug Des. & Discov., 1, 65-80, 2010.
315. Novel three-component domino reactions of ketones, isatin and amino acids: Synthesis and discovery of antimycobacterial activity of highly functionalised novel dispiropyrrolidines. R. S. Kumar, S. Perumal, D. Banerjee, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 45, 411-422, 2010.
316. Synthesis, in-vitro evaluation and computational studies of novel isatinyl derivatives for their activity against HIV-TB co-infection. D. Banerjee, P. Yogeeswari, P. Bhat, D. Sriram. Int. J. Drug Des. & Discov., 1, 65-80, 2010.
317. l-Proline-catalysed facile green protocol for the synthesis and antimycobacterial evaluation of [1,4]-thiazines. S. Indumathi, S. Perumal, D. Banerjee, P, Yogeeswari, D. Sriram. Eur. J. Med. Chem., 44, 4978-4984, 2009.
318. A facile domino protocol for the regioselective synthesis and discovery of novel 2-amino-5-arylthieno-[2,3-b]thiophenes as antimycobacterial agents. K. Balamurugan, S. Perumal, A. S. K. Reddy, P. Yogeeswari, D. Sriram. Tetrahedron Letters, 50, 6191-6195, 2009.
319. The anti-HIV-1 and antibacterial activities of two novel AZT-fuoroquinolones conjugates. J. Long, D. Sriram, G.H. Zhang, Y.T. Zheng. Chinese Pharmacological Bulletin 25, 30-34, 2009.
320. Novlel pthalazinyl derivatives: Synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis isocitrate lyase enzyme. D. Sriram, P.Yogeeswari, P. Senthilkumar, D. Sangaraju, R. Nelli, D. Banerjee, P. Bhat, B. Veugopal, V.V. S. Pavan, T.H Manjashetty. Med. Chem., 5, 422-433, 2009.
321. Current Approaches with the Glutamatergic System as Targets in the Treatment of Neuropathic Pain. P. Yogeeswari, Arvind Semwal, Ram Kumar Mishra, D. Sriram. Expert Opinion on Therapeutic Targets, 13, 925-943, 2009.
322. A facile synthesis and antimycobacterial evaluation of novel spiro-pyrido-pyrrolizines and pyrrolidines. R. R. Kumar, S. Perumal, P. Senthilkumar, P. Yogeeswari, D. Sriram. Eur. J. Med. Chem. 44, 3821-3829, 2009.
323. An atom economic synthesis and antitubercular evaluation of novel spiro-cyclohexanones R. R. Kumar, S. Perumal, S. C. Manju, P. Bhat, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. Lett. 19, 3461-3465, 2009.
324. A microwave assisted facile regioselective Fischer Indole synthesis and antitubercular evaluation of novel 2-aryl-3,4-dihydro-2H-thieno[3,2-b]indoles. S. V. Karthikeyan, S. Perumal, Krithika A. S., P. Yogeeswari, D. Sriram and K. K. Balasubramanian. Bioorg. Med. Chem. Lett. 19, 3006-3009, 2009.
325. Synthesis of zidovudine derivatives with anti-HIV-1 and antibacterial activities. P. Senthilkumar, J. Long, R. Swetha, V. Shruthi, R.Wang, S. Preethi, P. Yogeeswari, Y.T. Zheng, D. Sriram. Nucleosides, Nucleotides, & Nucleic Acids, 28, 89-102, 2009.
326. Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids. P. Senthilkumar, M. Dinakaran, P. Yogeeswari, D. Sriram, A. China, V. Nagaraja. Eur J Med Chem. 44, 345-358, 2009.
327. 5-Nitrofuran-2-yl derivatives: Synthesis and inhibitory activities against growing and dormant mycobacterium species. D. Sriram, P. Yogeeswari, P. Dhakla, P. Senthilkumar, D. Banerjee, T.H. Manjashetty. Bioorg. Med. Chem. Lett. 19, 1152-1154, 2009.
328. Antimycobacterial activity of novel N-(substituted)-2-isonicotinoylhydrazinocarbothioamide endowed with high activity towards isoniazid resistant tuberculosis. D. Sriram, P. Yogeeswari, Y. Priya. Biomed. Pharmacother. 63, 36-39, 2009.
329. Efavirenz Mannich bases: Synthesis, anti-HIV and anitubercular activities. D. Sriram, D. Banerjee, P. Yogeeswari. J. Enzyme Inhib. Med. Chem. 24, 1-5, 2009.
330. Antitubercular activities of novel benzothiazolo naphthyridone carboxylic acid derivatives endowed with high activity toward multi-drug resistant tuberculosis. M. Dinakaran, P. Senthilkumar, P. Yogeeswari, D. Sriram. Biomed. Pharmacother. 63, 11-18, 2009.
331. Synthesis and In-vitro Antimycobacterial Evaluation of Newer 1-(cyclopropyl/2,4-difluorophenyl/t-butyl)-1,4-dihydro-8-methyl-6-nitro-4-oxo-7-(substituted secondary amino)-quinoline-3-carboxylic acids. P. Senthilkumar, M. Dinakaran, Y. Chandraseakaran, P. Yogeeswari, D. Sriram. Arch. Pharm. 342, 100-112, 2009.
332. Antimycobacterial activities of novel fluoroquinolones. P. Senthilkumar, M. Dinakaran, P. Yogeeswari, A. China, V. Nagaraja, D. Sriram. Biomed. Pharmacother. 63, 27-35, 2009.
333. Cyclization of the semicarbazone template of aryl semicarbazones: synthesis and anticonvulsant activity of 4,5-diphenyl-2H-1,2,4-triazol-3(4H)-one. M. Shalini, P. Yogeeswari, D. Sriram, J.P. Stables. Biomed. Pharmacother. 63, 187-193, 2009.
334. A highly atom economic, chemo-, regio- and stereoselective synthesis, and discovery of spiro-pyrido-pyrrolizines and pyrrolidines as antimycobacterial agents. R.R. Kumar, S. Perumal, P. Senthilkumar, P. Yogeeswari, D. Sriram. Tetrahedron, 64, 2962-2971, 2008.
335. Discovery of antimycobacterial spiro-piperidin-4-ones: an atom economic, stereoselective synthesis, and biological intervention. R.R. Kumar, S. Perumal, P. Senthilkumar, P. Yogeeswari, D. Sriram. J. Med. Chem. 51, 5731-5735, 2008.
336. Synthesis, antimycobacterial activities and phototoxic evaluation of 5H-thiazolo[3,2-a]quinoline-4-carboxylic acid derivatives. M. Dinakaran, P. Senthilkumar, P. Yogeeswari, A. China, V. Nagaraja, D. Sriram. Med. Chem. 4, 482-491, 2008.
337. Newer N-phthaloyl GABA derivatives with antiallodynic and antihyperalgesic activities in both sciatic nerve and spinal nerve ligation models of neuropathic pain. P. Yogeeswari, J.V. Ragavendran, D. Sriram, R. Kavya, K. Vanitha, H. Neelakantan. Pharmacology., 81, 21-31, 2008.
338. Synthesis, anti-HIV and antitubercular activities of nelfinavir diester derivatives. D. Sriram, P. Yogeeswari, M. Dinakaran, M. Sowmya. Biomed. Pharmacother., 62, 1-5, 2008.
339. Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids. P. Senthilkumar, M. Dinakaran, D. Banerjee, R.V. Devakaram, P. Yogeeswari, A. China, V. Nagaraja, D. Sriram. Bioorg. Med. Chem., 16, 2558-2569, 2008.
340. Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid. M. Dinakaran, P. Senthilkumar, P. Yogeeswari, A. China, V. Nagaraja, D. Sriram. Bioorg Med Chem., 16, 3408-3418, 2008.
341. Antimycobacterial and phototoxic evaluation of novel 6-fluoro/nitro-4-oxo-7-(sub)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid. M. Dinakaran, P. Senthilkumar, P. Yogeeswari, A. China, V. Nagaraja, D. Sriram. Int. J. Antimicrob. Agents., 31, 337-344, 2008.
342. N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis virus infection in vitro and in vivo. L. Sebastian, A. Desai, M.N. Shampur, P. Yogeeswari, D. Sriram, Vasanthapuram R. Virol. J., 5:64, 2008.
343. Newer GABA derivatives for the treatment of epilepsy including febrile seizures: A bioisosteric approach. Ragavendran J.V., Sriram D, Kotapati S, Stables J, Yogeeswari P. Eur. J..Med. Chem., 43, 2650-2655, 2008.
344. Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation. M. Dinakaran, P. Senthilkumar, P. Yogeeswari, A. China, V. Nagaraja, D. Sriram. Bioorg. Med. Chem. Lett. 18, 1229-1236, 2008.
345. Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. D. Sriram, P. Senthilkumar, M. Dinakaran, P. Yogeeswari, A. China, V. Nagaraja. J. Med. Chem., 50, 6232-6239, 2007.
346. Heteroaryl-substituted semicarbazones: Synthesis and anticonvulsant activity of N-(3-Methylpyridin-2-yl)-substituted semicarbazones. S. Mehta, P. Yogeeswari, Roheeth Kumar, D. Sriram. J. Het. Chem., 43, 1287-1293, 2007.
347. Antimycobacterial activity of novel 1-(5-cyclobutyl-1,3-oxazol-2-yl)-3-(sub)phenyl/pyridylthiourea endowed with high activity toward multi-drug resistant tuberculosis. D. Sriram, P. Yogeeswari, M. Dinakaran, R. Thirumurugan. J. Antimicrob. Chemother. 59, 1194-1196, 2007.
348. Discovery of 4-Aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: A Hybrid pharmacophore approach. P. Yogeeswari, J. Vaigunda Ragavendran, D. Sriram, Y. Nageswari, R. Kavya, N. Sreevatsan, K. Vanitha, J. Stables. J. Med. Chem., 50, 2459-2467, 2007.
349. Synthesis and Antimicrobial Activities of Some Novel Substituted 2-Imidazolyl-N-(4-oxo-quinazolin-3(4H)-yl)-acetamides. N.M. Raghavendra, P. Thampi, P.M. Gurubasavarajaswamy, D. Sriram Chem. Pharm. Bull. 55, 1615-1619, 2007.
350. An atom efficient, solvent-free, green synthesis and antimycobacterial evaluation of 2-amino-6-methyl-4-aryl-8-[(E)-arylmethylidene]-5,6,7,8-tetrahydro-4H-pyrano[3,2-c]pyridine-3-carbonitriles. R.R. Kumar, S. Perumal, P. Senthilkumar, P. Yogeeswari, D. Sriram Bioorg. Med. Chem. Lett. 17, 6459-6462, 2007.
351. Synthesis, antitubercular and anticancer activities of substituted furyl-quinazolin-3(4H)-ones. N.M. Raghavendra, P. Thampi, P.M. Gurubasavarajaswamy, D. Sriram. Arch. Pharm. (Weinheim). 340, 635-641, 2007.
352. Synthesis and antitubercular activities of 1-(cyclopropyl/t-butyl/4-fluorophenyl)-1,4-dihydro-6-nitro-4-oxo-7-(substituted secondary amines)-1,8-naphthyridine-3-carboxylic acid. P. Senthil Kumar, M. Dinakaran, P. Yogeeswari, D. Sriram. Med. Chem. Res., 15, 281-282, 2007.
353. N-Hydroxythiosemicarbazones: Synthesis and in-vitro antitubercular activity. D. Sriram, P. Yogeeswari, Prathiba Dakhla, P. Senthil Kumar, Debjani Banerjee. Bioorg. Med. Chem. Lett., 17, 1888-1893, 2007.
354. Isatin derivatives inhibit Japanese encephalitis virus entry and replication in-vitro. D. Banerjee, T.R. Bal, P. Yogeeswari, D. Sriram, L. Sebastin, A. Desai, S.N. Madhusudhana, V. Ravi. Med. Chem. Res., 15, 133-135, 2007.
355. Microwave-assisted Synthesis, Anticonvulsant activity and Quantum Mechanical modeling of N-(4-Bromo-3-methylphenyl)semicarbazones. Shalini, P. Yogeeswari, D. Sriram, S. Induja. J. Zhejiang Univ. Section B (Springer), 8, 45-55, 2007.
356. Synthesis of 4-{[(3Z)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]amino}-N-substituted phenyl) butanamides possessing antiallodynic and antihyperalgersic activities in two rat models of neuropathic pain. J.V. Ragavendran, I. Vikram Reddy, P. Yogeeswari, D. Sriram. Med. Chem. Res., 15, 225-226, 2007.
357. Design and Synthesis of Anticonvulsants from a Combined Phthalimide-GABA –Anilide and Hydrazone Pharmacophore. J. V. Ragavendran, D. Sriram, S.K. Patel, I. Vikram Reddy, N. Bharathwajan, J. Stables, P. Yogeeswari. Eur. J. Med. Chem., 42, 146-151, 2007.
358. Neuropathic pain: Strategies in drug discovery and treatment. P. Yogeeswari, J.V. Ragavendran, D. Sriram. Expert Opinion on Drug Discovery, 2, 169-184, 2007.
359. 5-Nitro-2-furaldehyde thiosemicarbazones: Synthesis and in-vitro antimycobacterial activities. K.N. Purna, P. Dhakla, P. Senthil Kumar, P. Yogeeswari, D. Sriram. Med. Chem. Res., 15, 223-224, 2007.
360. Synthesis of various 7-substituted-1-t-butyl-1,4-dihydro-8-methyl-6-nitro-4-oxo quiniline-3-carboxylic acid. M. Dinakaran, C. Yogesh, P. Yogeeswari, D. Sriram. Med. Chem. Res., 15, 328, 2007.
361. Newer Tetracycline derivatives: Synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase. D. Sriram, P. Yogeeswari, G. Senchani, D. Banerjee. Bioorg. Med. Chem. Lett.,17, 2372-2375, 2007.
362. Synthesis and in-vitro anti-HIV activities of Didanosine prodrugs. D. Sriram, P. Yogeeswari, N. Raveendra Babu, K.N. Purna. J. Enzyme Inhib.,22, 51-55, 2007.
363. Synthesis and anticonvulsant activity of 4-(2-(2,6-dimethylphenylamino)-2-oxoethylamino)-N-(substituted)butanamides: A Pharmacophoric hybrid approach. P. Yogeeswari, D. Sriram, P. Sahitya, J.V. Ragavendran, V. Ranganadh. Bioorg. Med. Chem. Lett., 17, 3712-3715, 2007.
364. Pharmacological screening of candidate anticonvulsants in the animal model of febrile seizures. A.S.K. Reddy, J.V. Ragavendran, P. Yogeeswari, D. Sriram. Med. Chem. Res., 15, 285-286, 2007.
365. Synthesis and anti-HIV activity of N'-nicotinoyl--3-(4'-hydroxy-3'-methylphenyl)-5-[substituted phenyl]-2-pyrazolines. M.A. Ali, M.S. Yar, A.A. Siddiqui, D. Sriram, P. Yogeeswari, E. De Clercq. Acta. Pol. Pharm., 64, 423-428, 2007.
366. Discovery of lesser neurotoxic and effective anticonvulsant agents active in four animal models of seizure. D. Sriram, M. Shalini. Neurol. Asia, 12, 111-112, 2007.
367. Synthesis and anti-HIV activity of nevirapine prodrugs. D. Sriram, P. Yogeeswari, M.R. Kishore Pharmazie., 61, 895-897, 2006.
368. Synthesis and antimicrobial activity of 3-(4'-hydroxy-3'-methylphenyl)-5-[(substuted) phenyl]-4,5-dihydro-1H-1-pyrazolyl-4-pyridylmethanone derivatives. M.S. Yar, M.A. Ali, D. Sriram, P. Yogeeswari. Acta. Pol. Pharm., 63, 491-496, 2006.
369. Quantum mechanical modeling of N4-(2, 5-disubstituted phenyl) semicarbazones: synthesis and anticonvulsant activity of N4-(2, 5-dimethylphenyl/ -2-fluoro-5-methyl phenyl) semicarbazones. M. Shalini, P. Yogeeswari, D. Sriram, P. Kudyar, P.R. Kumar, S. Induja, J.P. Stables Med. Chem., 2, 617-625, 2006.
370. Discovery of Newer Antitubercular Oxazolyl thiosemicarbazones. D. Sriram, P. Yogeeswari, R. Thirumurugan, P. Roheeth Kumar. J. Med. Chem. 49, 3448-3450, 2006.
371. Synthesis and in-vitro antitubercular activity of some 1-[(4-sub)phenyl]- 3-(4-{1- [(pyridine-4-carbonyl)hydrazono]ethyl phenyl) thiourea. D. Sriram, P. Yogeeswari, K. Madhu. Bioorg. Med. Chem. Lett. 16, 876-878, 2006.
372. Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydrazones and amides. D. Sriram, P. Yogeeswari, R.V. Devakaram. Bioorg. Med. Chem., 14, 3113-3118, 2006.
373. Synthesis of Pyrazinamide Mannich bases and its antitubercular properties. D. Sriram, P. Yogeeswari, S.P. Reddy Bioorg. Med. Chem. Lett., 16, 2113-2116, 2006.
374. Gatifloxacin derivatives: Synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. D. Sriram, A. Aubry, P. Yogeeswari, L.M. Fischer. Bioorg. Med. Chem. Lett., 16, 2982-2985, 2006.
375. Design, synthesis, anti-HIV and antitubercular activities of isatin derivatives. D. Sriram, P. Yogeeswari, K. Meena. Pharmazie, 61, 271-274, 2006.
376. An Update on GABA Analogs for CNS Drug Discovery. P. Yogeeswari, J.V. Ragavendran, D. Sriram. Recent Patent on CNS Drug Discov., Vol 1 (First issue) 113-118, 2006.
377. Synthesis and structure-activity relationship on anticonvulsant aryl semicarbazones. P. Yogeeswari, D. Sriram, J. Vaigunda Raghavendran, R. Thirumurugan, S. Induja, J.P. Stables. Med. Chem., 2, 55-62, 2006.
378. 2,4-Dimethoxyphenyl semicarbazones with anticonvulsant activity against three animal models of seizure: Synthesis and Pharmacological evaluation P. Yogeeswari, D. Sriram, R. Thirumurugan, J.P. Stables Bioorg. Med. Chem., 14, 3106-3112, 2006.
379. Epibatidine and its analogues as nicotinic acetylcholine receptor agonist. An update. P. Yogeeswari, D. Sriram, R.Thirumurugan, T. R. Bal Nat. Prod. Res., 20, 497-505, 2006.
380. Synthesis of some new semicarbazone derivatives as anticonvulsants with GABA- mediated mechanism. P. Yogeeswari, R.Thirumurugan, D. Sriram, L.R.J. Suniljit, J. Vaigunda Ragavendran, R. Kavya, K. Rakhra, J.P. Stables. Acta. Pharm., 56, 259-272, 2006.
381. Synthesis and in-vitro antimycobacterial activity of N1-Nicotinoyl-3-(4’-hydroxy-3’-methyl phenyl)-5-[(sub)phenyl]-2-pyrazolines. M. Shaharyar, A.A. Siddiqui, M. Asharaf Ali, D. Sriram, P. Yogeeswari. Bioorg. Med. Chem. Lett., 16, 3947-3949, 2006.
382. Abacavir prodrugs: Microwave-assisted synthesis and their evaluation of anti-HIV activities. D. Sriram, P. Yogeeswari, N.S. Myneedu, V. Saraswat. Bioorg. Med. Chem. Lett., 16, 2127-2129, 2006.
383. Evaluation of antimycobacterial and DNA gyrase inhibition of fluoroquinolone derivatives. D. Sriram, T. R. Bal, P. Yogeeswari, D.R. Radha, V. Nagaraja. J. Gen. App. Microbiol., 52, 195-200, 2006.
384. Discovery of N-(2,6-Dimethylphenyl) substituted Semicarbazones as Anticonvulsants : Hybrid Pharmacophore-based design P. Yogeeswari, D. Sriram, R. Thirumurugan, J.V. Raghavendran, K. Sudhan, Roheeth Kumar, J. Stables. J. Med. Chem., 48, 6202-6211, 2005.
385. Aminopyrimidinimino isatin analogues: Design and synthesis of novel non- nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum anti-microbial properties D. Sriram, T. R. Bal, P. Yogeeswari. Med. Chem., 1, 277-285, 2005.
386. Newer aminopyrimidinimino isatin analogues as non-nucleoside HIV-1 reverse transcriptase inhibitors for HIV and other opportunistic infections of AIDS: Design, synthesis and biological evaluation. D. Sriram, T. R. Bal, P. Yogeeswari. Farmaco, 60, 377-384, 2005.
387. The GABA shunt: An attractive and potential therapeutic target in the treatment of epileptic disorders. P. Yogeeswari, D. Sriram, J.V. Raghavendran, R. Thirumurugan. Curr. Drug Metabolism, 6, 127-140, 2005.
388. Combinatorial Synthesis of anti-HIV-1 agents. D. Sriram, P.Yogeeswari, A.N. Nagappa. Comb. Chem. High Throughput Screen., 8(6), 377-385, 2005.
389. Camptothecin and its analogues: A review on their chemotherapeutic potential. D. Sriram, P. Yogeeswari, R.Thirumurugan, T. R. Bal. Nat. Prod. Res., 19, 393-412, 2005.
390. Synthesis of Novel Aryl semicarbazones as Potential Anticonvulsant Agents. P.Yogeeswari, D. Sriram, V.Veena, R.Kavya, K.Rakhra, S.Mehta, J.VaigundaRagavendran, R.Thirumurugan, J.P.Stables. Biomed. Pharmacother., 59, 51-55, 2005.
391. Anticonvulsant and neurotoxicity evaluation of some 6-substituted benzothiazolyl-2-thiosemicarbazones. P. Yogeeswari, D. Sriram, S. Mehta, D. Nigam, M. Mohan Kumar, S. Murugesan, J.P. Stables. Farmaco, 60 (1), 1-5, 2005.
392. Betulinic acid and its derivatives: A review on their biological properties. P. Yogeeswari and D. Sriram Curr. Med. Chem., 12 (3), 763-771, 2005.
393. Synthesis and Antimycobacterial evaluation of various 7- Substituted Ciprofloxacin Derivatives D. Sriram, P. Yogeeswari, J.S. Basha, D. R. Radha, V. Nagaraja. Bioorg. Med. Chem., 13, 5774-5778, 2005.
394. Synthesis and in-vitro antimycobacterial activity of some isonicotinyl hydrazones. D. Sriram, P. Yogeewari and K. Madhu. Bioorg. Med. Chem. Lett., 15, 4502-4505, 2005.
395. Synthesis and evaluation of anti-HIV activity of isatin β-thiosemicarbazone derivatives. T.R. Bal, B. Anand, P. Yogeeswari, D. Sriram. Bioorg. Med. Chem. Lett., 15, 4451-4455, 2005.
396. Microwave-assisted synthesis, and anti-YFV activity of 2, 3-diaryl-1, 3-thiazolidin-4-ones D. Sriram, P. Yogeeswari, T.G. Ashok Kumar J. Pharm. Pharm. Sci., 8, 429-466, 2005.
397. Synthesis of zidovudine prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. D. Sriram, P. Yogeeswari, N. Srichakravarthy, T. R. Bal. Biomed. Pharmacother. 59, 452-455, 2005.
398. Nevirapine derivatives with broad spectrum chemotherapeutic properties for the effective treatment of HIV / AIDS. D. Sriram, P. Yogeeswari, N. Srichakravarthy, T. R. Bal. Biomed. Pharmacother., 59, 456-459, 2005.
399. Microwave-assisted synthesis, anti-HIV activity of 2, 3-diaryl-1, 3-thiazolidin-4-ones. D. Sriram, P. Yogeeswari, T.G. Ashok Kumar. Ind. J. Pharm. Sci., 67, 496-499, 2005.
400. Microwave Assisted Synthesis, Anti-HIV, and Anti-YFV Activities of Schiff Bases of N-Hydroxy-N1-Aminoguanidine tosylate. D. Sriram, P. Yogeeswari, T.G. Ashok Kumar. Ind. J. Pharm. Sci., 67, 493-496, 2005.
401. Aminopyrimidinimino isatin analogues: Design of novel non- nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties. D. Sriram, T. R. Bal, P. Yogeeswari. J. Pharm. Pharm. Sci., 8, 565-577, 2005.
402. Synthesis and in-vitro cytotoxicity evaluation of gatifloxacin Mannich bases. P. Yogeeswari, D. Sriram, R. Kavya, S. Tiwari. Biomed. Pharmacother., 59, 501-510, 2005.
403. Synthesis, anti-HIV and antitubercular activities of lamivudine prodrugs. D. Sriram, P. Yogeeswari, Gayatri Gopal. Eur. J. Med. Chem., 40, 1373-1376, 2005.
404. Design, synthesis and biological evaluation of novel non- nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum antimicrobial properties: Aminopyrimidinimino isatin analogues. D. Sriram, T. R. Bal, P. Yogeeswari. Med. Chem. Res., 14, 211-228, 2005.
405. Progress in the research of artemisinin and its analogues as anti-malarials: an update D. Sriram, V. S. Rao, K. V. G. Chandrasekhar and P. Yogeeswari. Nat. Prod. Res., 18(6), 503-527, 2004.
406. Design, synthesis and biological evaluation of novel non- nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties. D. Sriram, T. R. Bal, P. Yogeeswari. Bioorg. Med. Chem., 12, 5865-5873, 2004.
407. Ion channels as important targets for antiepileptic drug design. P.Yogeeswari, J. Vaigunda Raghavendran, R. Thirumurugan, A. Saxena. , D. Sriram. Curr. Drug Targets, 5, 589-602, 2004.
408. Antituberculous activity of some aryl semicarbazones derivatives. D. Sriram, P. Yogeeswari, R. Thirumurugan. Bioorg. Med. Chem. Lett., 15, 3923-3924, 2004.
409. 4-Sulphamoylphenyl semicarbazones with anticonvulsant activity. P. Yogeeswari, D. Sriram, S.N. Pandeya, J.P. Stables. Farmaco, 59, 609-613, 2004.
410. 2-Methyl, 3-chlorophenyl-substituted semicarbazones: Synthesis and anticonvulsant activity. P. Yogeeswari, R. Thirumurugan, R. Kavya, J. Selwyn Samuel, J.P. Stables, D. Sriram. Eur. J. Med. Chem., 39, 729-734, 2004.
411. Synthesis of Tetrahydro-2H-[1, 3, 5] thiadiazine-5-(4-pyridylcarboxamido)-2-thione with antitubercular activity. D. Sriram, K. Jyothi Mallika and P. Yogeeswari. Sci. Pharm., 75, 35-41, 2004.
412. Synthesis of Stavudine Amino acid Ester Prodrugs with Broad-Spectrum Chemotherapeutic Properties for the Effective Treatment of HIV/AIDS. D. Sriram, P. Yogeeeswari, N. Srichakravarthy, Tanushree Ratan Bal. Bioorg. Med. Chem. Lett., 14, 1085-1087, 2004.
413. Synthesis of novel aryl semicarbazones as anticonvulsants with GABA-mediated mechanism. P.Yogeeswari, D. Sriram, A.Brahmandam, I.Sridharan, R.Thirumurugan and J.P. Stables. Med. Chem. Res., 12(2), 57-68, 2003.
414. Synthesis and Anticonvulsant and Neurotoxicity Evaluation of N4 –Phthalimido Phenyl (Thio) Semicarbazides. P.Yogeeswari, D. Sriram, V.Saraswat, J.Vaigunda Ragavendran, M.Mohan Kumar, S.Murugesan, R.Thirumurugan, J.P.Stables. Eur. J. Pharm. Sci., 20, 341-346, 2003.
415. Towards the Design and Development of Agents with Broad Spectrum Chemotherapeutic Properties for the Effective Treatment of HIV / AIDS. D. Sriram, P.Yogeeswari. Curr. Med. Chem., 10, 1909-1915, 2003.
416. Antibacterial and antifungal activities of N-Mannich bases of 3-[N2-pyrimethaminylimino] isatin. S.N.Pandeya, P.Yogeeswari, D. Sriram, G.Nath. Ind. J. Pharm. Sci., 64, 209-212, 2002.
417. Antituberculous activity of isatin derivatives. D. Sriram, P.Yogeeswari, S.N.Pandeya, S. Ananthan. Sci. Pharm., 70, 73-79, 2002.
418. Anticonvulsant and neurotoxicity evaluation of some 6-chlorobenzothiazolyl-2-thiosemicarbazones. P.Yogeeswari, D. Sriram, L.R.J. Suniljit, S.S.Kumar, J.P.Stables. Eur. J. Med. Chem., 37, 231-236, 2002.
419. Antituberculous activity of Norfloxacin Mannich bases with Isatin derivatives. S.N. Pandeya, D. Sriram, P.Yogeeswari, S. Ananthan. Chemotherapy, 47, 266-269, 2001.
420. Anticonvulsant and Neurotoxicity evaluation of 5-(un)-substituted isatinimino derivatives. S.N.Pandeya, D. Sriram, P.Yogeeswari, J.P. Stables. Pharmazie, 56, 875-878, 2001.
421. Anti-HIV and antibacterial activities of some disubstituted quinazolones and their Bio-isostere Disubstituted thienopyrimidones. V. Alagarsamy, U.S. Pathak, D. Sriram, S.N. Pandeya, E. De Clercq. Ind. J.Pharm Sci. 62(6), 433-437, 2000.
422. Synthesis, antibacterial, antifungal and anti-HIV activity of Schiff and Mannich bases of Isatin with N- [6-chlorobenzothiazol-2-yl] thiosemicarbazide. S.N. Pandeya, D. Sriram, G. Nath, E. De Clercq. Ind. J. Pharm Sci. 61(6). 358-361, 2000.
423. Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of Isatin and its derivatives with Triazole. S.N. Pandeya, D. Sriram, G.Nath, E.De Clercq. Arzneim-Forsch./Drug Res. 50(1), 55-59, 2000.
424. Synthesis, antibacterial, antifungal and anti-HIV activities of norfloxacin Mannich bases. S.N. Pandeya, D. Sriram, G. Nath, E.De Clercq. Eur, J. Med. Chem. 35, 249-265, 2000.
425. Synthesis and antimicrobial activity of Schiff and Mannich bases of Isatin and its derivatives with pyrimidine. S.N.Pandeya, D. Sriram, G.Nath, E.De Clercq. Farmaco, 54, 624-628, 1999.
426. Synthesis and Screening for Anti-HIV activity of some N-Mannich bases of isatin derivatives. S.N. Pandeya, P.Yogeeswari, D. Sriram, E. De Clercq, C. Pannecouque, M. Witvrouw. Chemotherapy, 45, 192-196, 1999.
427. Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-methyl mercapto quinazolin –4(3H)- one. S.N. Pandeya, D. Sriram, G.Nath, E.De Clercq. Pharm. Act. Helv., 74, 11-17, 1999.
428. Synthesis, antibacterial, antifungal and anti-HIV evaluation of Norfloxacin Mannich bases. S.N. Pandeya, D. Sriram, G.Nath, E.De Clercq. Sci. Pharm. 67, 103-111, 1999.
429. Synthesis, antibacterial, antifungal and anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4’-Chlorophenyl) thiazol-2-yl] thiosemicarbazide. S.N. Pandeya, D. Sriram, G. Nath, E.De Clercq. Eur. J. Pharm. Sci. 9, 25-31, 1999.
430. Synthesis and evaluation of some novel Schiff’s and Mannich bases of Indole-2,3-diones as potential antibacterial, analgesic and anti-inflammatory agents. S.N.Pandeya, D. Sriram, V.Alagarsamy. Acta Pharm. Turc. XLI(4), 153-158, 1999.
431. Synthesis and antibacterial activity of Mannich bases of Ciprofloxacin and Lomefloxacin with Isatin and its derivative. S.N.Pandeya, C.G.Sundari, N.Mariammal, P.Saravanan, S.S. Balaji, R.S.Kumar, D. Sriram. Ind. J. Pharm. Sci. 60(5), 280-282, 1998.
432. Synthesis and screening for antibacterial activity of Schiff’s and Mannich bases of Isatin and its derivatives. S.N.Pandeya, D. Sriram. Acta Pharm. Turc. 40(10), 33-38, 1998.
433. Synthesis and antimicrobial activity of N-Mannich bases of 3-[N’-sulphadoximino] Isatin and its methyl derivative. S.N.Pandeya, P.Yogeeswari, D. Sriram, G.Nath. Boll. Chim. Farm. 137(8), 321-324, 1998.
434. Anti-HIV activity of some Mannich bases of isatin derivatives. S.N. Pandeya, D. Sriram, E. De Clercq; C. Pannecouque, M. Witvrouw. Ind. J. Pharm. Sci. 60(4), 207-212, 1998.